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Abstract 
Orexin is a neuropeptide with a large range of functions, with a recently 
discovered role in blood pressure (BP) regulation. Although the role of brain orexin 
system in hypertension has been investigated in several hypertensive animals, it 
remains unclear whether activation of the orexin system contributes to the 
development of Deoxycorticosterone-acetate (DOCA) hypertension, an animal 
model of human salt sensitive hypertension. In this study, we investigated the 
hypothesis that Orexin-1 receptor (OX1R) expression is increased in the 
paraventricular nucleus (PVN), a critical brain area controlling cardiovascular 
function, which subsequently increases vasopressin (AVP) expression and 
peripheral secretion, resulting in hypertension development in this model. Seven 
to eight-week-old male Sprague Dawley (SD) rats were split into three groups 
including DOCA-salt, untreated controls, and OX1RshRNA-DOCA rats. Following 
knockdown of OX1R in the PVN via viral infection in the OX1RshRNA-DOCA rats, 
they, as well as the DOCA-salt group, were implanted with a 75mg DOCA pellet 
and treated with 1%NaCl/0.2%KCl drinking water, while the control group 
remained untreated. Blood pressure of each rat was measured using tail-cuff 
plethysmography. Three weeks following DOCA-salt or sham treatment, all rats 
were sacrificed, and brains were subjected to either real-time PCR or 
immunostaining to assay mRNA level and protein expression of Orexin A, OX1R, 
and AVP in the PVN. Their blood was collected for plasma AVP measurement, 
and their hearts were weighed for measurement of their heart weight/body weight 
(BW/HW) ratio. Our results showed that chronic knockdown of the PVN OX1R 
effectively attenuated hypertension induced by DOCA-salt treatment (control: 
107.91±5.99 vs. DOCA-salt: 142.43±7.73 vs. DOCA+OX1RshRNA: 115.69±8.23 
mmHg; P<0.01)   PCR data showed the mRNA levels of OX1R was increased by 
23%, while vasopressin showed more than a 2-fold increase in the PVN of DOCA-
salt rats compared to controls. Immunostaining data showed a dramatic increase 
in OX1R as well as vasopressin expression within the PVN following DOCA-salt 
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treatment, and both increases were attenuated following PVN OX1R knockdown. 
Plasma AVP levels also showed a significant increase following DOCA-salt 
treatment (control: 9.04±2.57 vs. DOCA-salt: 37.94±8.66 pg/ml; P<0.05), and 
PVN OX1R significantly attenuated this (DOCA-OX1RshRNA: 0.644±0.281, 
P<0.05). The heart weight to body weight ratio was also measured to be larger in 
the DOCA-salt group when compared to the control group (Control: 0.31±0.011%, 
vs DOCA-salt: 0.40±0.017%, P<0.005), while the OX1RshRNA injection 
appeared to mitigate this increase (OX1RshRNA: 0.35±0.019%, vs DOCA-salt: 
DOCA-salt: 0.40±0.017%). The combination of this data shows a potential role for 
orexin in the pathology of salt-sensitive hypertension development. 
1 
1 Introduction 
1.1 Overview 
Hypertension is a major pathological condition that affects millions of 
individuals, and approximately one-third of adults in the United States alone 
(Centers for Disease and Prevention 2011). Along with the various 
pathophysiological traits that accompany the onset of hypertension, individuals 
who are affected are also at an increased risk for devastating cardiovascular 
diseases, such as cardiac ischemia, hearty failure, and stroke (Klungel, Kaplan et 
al. 2000, Drazner 2011, Turin, Okamura et al. 2016), both of which raise the 
likelihood of death due to cardiovascular complications. A plethora of studies have 
found that the majority of individuals who are diagnosed with primary hypertension 
are often known as salt-sensitive, meaning that sodium handling and pressor 
responses following a salt challenge are faulty, leading to an increase and 
maintenance of an abnormally high blood pressure  (Weinberger 1996, Whelton, 
Appel et al. 2012, O'Donnell, Mente et al. 2015). Although it is estimated that 
slightly more than half of individuals diagnosed with high blood pressure are 
considered salt-sensitive (Weinberger, Miller et al. 1986), very little is known about 
the molecular mechanism underlying the abnormal response to sodium intake. 
Because of this, it is important to produce new knowledge and deeper insight into 
the mechanism underlying Salt-Sensitive Hypertension (SSH) to decrease its 
prevalence in the general population, thus decreasing cardiovascular disorders, 
as well as the associated mortality rate. 
1.2 Blood Pressure Regulation 
Current American Heart Association guidelines for hypertension state that a 
blood pressure of 120/80 mmHg is classified as normotensive (Whelton, Carey et 
al. 2018). To maintain a relatively constant blood pressure, the body has 
employed various means of regulating this stable environment. Mean arterial 
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pressure (MAP) is defined as the average blood pressure experienced by an 
individual over one cardiac cycle. MAP is the product of both cardiac output (CO) 
and total peripheral resistance (TPR). This offers two variables that must be in 
working condition to efficiently regulate blood pressure. However, there are 
numerous ways in which the body can modify CO as well as TPR, specifically 
through autonomic and neural-hormonal signaling, which act as short-term and 
long-term means of blood pressure management. 
1.2.1 Short Term Blood Pressure Regulation: Autonomic Influences 
As the heart pumps blood throughout the body, the cardiovascular system 
is notified on a beat-by-beat basis of any abnormalities in blood flow, primarily by 
the action of the two branches of the autonomic nervous system (ANS): the 
parasympathetic nervous system (PNS) and the sympathetic nervous system 
(SNS). The PNS and SNS have antagonistic actions in relation to one another, 
although both are intrinsically active (Swenne 2013). The PNS serves as the 
mediator of action during resting phases, while the SNS elicits excitation and 
increased activity. In blood pressure regulation, the SNS innervates the sinoatrial 
(SA) node, also known as the pacemaker, in the right atrium of the heart, as well 
as the myocardium. Because of this, when activated, the SNS can increase heart 
rate, as well as cardiac contractility, thus effecting stroke volume. The PNS 
opposes this action, and innervates the SA node through the vagus nerve, which, 
when activated, causes a decrease in heart rate. Along with this, innervation of 
blood vessels by the SNS results in vasoconstriction, which can also increase 
TPR.  
 The PNS and SNS are activated and regulated through the actions of 
baroreceptors. Baroreceptors function as mechanoreceptors, and are primarily 
located in both the carotid sinus and the aortic arch. These mechanoreceptors 
respond to any changes in the pressure against blood vessel walls that may 
indicate a dysfunction in the regular flow of blood through the cardiovasculature 
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(Charkoudian and Rabbitts 2009). When a change is observed by the 
mechanoreceptors, they activate the body’s intrinsic baroreflex mechanism 
(Charkoudian and Rabbitts 2009). When the mean arterial pressure is increased, 
the increase in blood volume stretches vessel walls and is sensed in both the 
aortic arch, as well as the carotid sinus, which are innervated by the vagus nerve 
and the glossopharyngeal nerve (Benarroch 2008), respectively. This immediately 
increases afferent signal firing frequency from the baroreceptors to the 
cardiovascular control center located within the medulla oblongata of the 
brainstem, specifically the nucleus tractus solitarius (NTS) (Guyenet 2006, 
Dampney 2016). The NTS acts as a key cardiovascular integration center, and 
functions to activate inhibitory interneurons through glutamate release within the 
caudal ventrolateral medulla (CVLM). The CVLM elicits an inhibitory effect 
through release of the neurotransmitter Gamma-Aminobutyric Acid (GABA) on the 
rostral ventrolateral medulla (RVLM) (Kumagai, Oshima et al. 2012), the location 
of many pre-sympathetic neurons and a key center for sympathetic output 
(Pilowsky and Goodchild 2002). This pathway causes a cessation of sympathetic 
efferent output, and an increase in PNS activity. This effectively decreases both 
heart rate and stroke volume, decreasing cardiac output, and causes vasodilation 
of the vasculature, reducing the total peripheral resistance, allowing the blood 
pressure to fall back to its normotensive state. If an individual becomes 
hypotensive, the opposite occurs, and sympathetic nerve activity is increased 
through a reduced inhibition of the RVLM, resulting in subsequent glutamatergic 
activation of sympathetic preganglionic neurons within the intermediolateral cell 
column (IML) (Guyenet 2006, Kumagai, Oshima et al. 2012), resulting in an 
increase in cardiac output as well as vasoconstriction, effectively raising blood 
pressure. Although this mechanism allows an efficient means of monitoring blood 
pressure on a short-term basis, it is not meant to be a long-term solution to blood 
pressure dysregulation. 
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1.2.2 Long Term Blood Pressure Regulation: Neural-Hormonal Influences 
To compensate for long term adaptations to blood pressure changes, the 
human body produces multiple hormones in response to changes in blood 
pressure, which can carry out their function over a much longer period of time. 
The Renin-Angiotensin-Aldosterone-System (RAAS) is the predominant controller 
of this hormonal response, and acts as the primary controller of long-term blood 
pressure regulation through modulation of both natriuresis and diuresis within the 
kidney tubules. When blood pressure lowers to a level that is classified as 
hypotensive, or the osmolality of the blood reaches a lower level than the norm, 
the kidneys will release renin, an important catalytic enzyme that facilitates the 
transformation of circulating Angiotensinogen to Angiotensin I (ANGI). 
Angiotensin Converting Enzyme (ACE) then turns Angiotensin I into Angiotensin 
II (ANGII). ANGII is arguably one of the most important, and potent hormones 
involved in blood pressure regulation. ANGII carries out its primary activity through 
two receptors, AT1 and AT2 receptors. Although the actions of ligand binding to 
AT2 receptors are not as well understood, binding of ANGII to its AT1 receptor 
facilitates an increase in sympathetic tone as well as vasoconstriction.  ANGII also 
heavily influences the synthesis and subsequent release of two major hormones, 
aldosterone and vasopressin (AVP) (Fig. 1.1).  
Further research has observed that ANGII may also have influences on brain 
function and subsequent synaptic activity through interaction with the central 
nervous system. All RAAS components have been found within the brain 
(McKinley, Allen et al. 2001, McKinley, Albiston et al. 2003, Pan 2004), indicating 
an intrinsic central mechanism for RAAS functioning. It is also worth mentioning 
that the bulk concentration of AT1 receptors, are found in major cardiovascular 
areas such as the PVN and Supraoptic Nucleus (SON) (Pan 2004). Studies have 
shown that an ANGII brain injection, whether it be intracerebroventricular (ICV) or 
through direct microinjection into the PVN, elicits an increase in blood pressure, 
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and antagonism of the AT1 receptor within the brain causes a dampening of the 
blood pressure increase (Jensen, Harding et al. 1992, Bahner, Geiger et al. 1995). 
Interestingly, it has also been observed that subcutaneous and peripheral 
injections of ANGII have shown an increase in AT1 receptors within the PVN, 
despite the presence of the blood brain barrier, which ANGII cannot readily cross 
(Wei, Yu et al. 2009). Although it cannot directly elicit a response on major brain 
areas, ANGII acts on AT1 receptors within Circumventricular Organs (CVO) such 
as the vascular organ of lamina terminalis (OVLT), subfornical organ (SFO), the 
median eminence, and the area postrema, all of which lack a blood brain barrier 
(Sunn, McKinley et al. 2003, Pan 2004). These brain regions have high 
concentrations of AT1 receptors (Pan 2004), as well as multiple projections to 
other brain areas, namely, projections from the SFO to the PVN (Kawano and 
Masuko 2010). This offers an explanation as to why peripheral actions of ANGII 
in response to lowered blood pressure, or changes in blood osmolality, can elicit 
a centrally mediated response in cardiovascular control centers, such as the PVN. 
Angiotensinogen ANGI ANGII
SNA +
Adrenal Gland
Posterior 
Pituitary
Vasoconstriction
Aldosterone
AVP
Na+ and H2O 
Reabsorption, 
K+ Secretion, 
↑BP
Decrease BP
Renin ACE
+
-
 
Figure 1.1: Diagram representing function of the Renin-Angiotensin-Aldosterone 
system (RAAS) in blood pressure regulation. Angiotensin I (ANGI), Angiotensin-
Converting Enzyme (ACE), Angiotensin II (ANGII), Sympathetic Nerve Activity (SNA), 
Arginine Vasopressin (AVP), Blood Pressure (BP). 
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1.2.2.1 Aldosterone and Arginine Vasopressin in Blood Pressure Regulation 
Aldosterone was first discovered in 1953, and since that time, it has been 
recognized as a major regulator of fluid and electrolyte balance within the kidney 
natriuresis/diuresis system. Aldosterone is a mineralocorticoid that is produced by 
the adrenal cortex upon stimulation from various factors, such as circulating 
ANGII, increased serum potassium levels, among others (Briet and Schiffrin 
2010). Upon activation and subsequent release from the adrenal glomerulosa, 
aldosterone acts on both glucocorticoid as well as mineralocorticoid receptors 
within the cytoplasm of target tissues, with a higher affinity for the latter (Muto 
1995). After binding to its receptor, the hormone-receptor complex will relocate to 
the nucleus of the cell, and mediate regulation of gene transcription (Muto 1995). 
These genes will then lead to the production of proteins that work to preserve fluid 
homeostasis within the body, specifically through regulation of electrolyte (sodium 
and potassium) levels within the bloodstream (Muto 1995, Summa, Mordasini et 
al. 2001). One of the downstream transcription regulation pathways occurs in cells 
of the distal convoluted tubule of the kidney, where binding of aldosterone causes 
downstream activation of epithelial sodium channels (ENaC) on the apical 
membrane of the epithelial cells, as well as Na+/K+ ATPase on the basolateral 
side, resulting in a net sodium, and subsequent water reabsorption, as well as 
potassium excretion into the urine (Summa, Mordasini et al. 2001, Briet and 
Schiffrin 2010). This process effectively increases blood osmolality as well as 
volume, making it essential to proper functioning of the complete RAAS system 
(Fig. 1.2). 
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Figure 1.2: Representation of aldosterone action on cells of the distal collecting 
tubule of the kidney. Mineralocorticoid receptor (MR), Sodium/Potassium ATPase 
(ATPase), endothelial sodium channel (ENaC), sodium (Na+), potassium (K+). 
Another key hormone in cardiovascular and fluid homeostasis is Arginine 
Vasopressin (AVP). AVP is produced in both magnocellular as well as 
parvocellular neurons located in both the (PVN) of the Hypothalamus as well as 
the SON (Treschan and Peters 2006). It is primarily activated by an increase in 
plasma osmolality, decreased blood volume, as well as decreased arterial 
pressure (Treschan and Peters 2006). Through its action on its three receptor 
types (V1, V2, V3), AVP can elicit multiple physiological responses. Worth noting, 
AVP specifically causes vasoconstriction through its interaction with V1 receptors 
on smooth muscle cells, and causes water reabsorption through relocation of 
aquaporins on the collecting ducts of the kidney through its interaction with V2 
receptors (Thibonnier, Berti-Mattera et al. 1998, Bankir, Fernandes et al. 2005, 
Treschan and Peters 2006). The V1 and V2 receptors are two different types of 
G-protein Coupled Receptors (GPCRs), with differing downstream signaling 
cascades. The V1 cascade involves interaction with phospholipase C (PLC) 
following conformational change of the GPCR upon substrate binding. PLC then 
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acts to facilitate the cleavage of inositol 4,5 – bisphosphate (PIP2) into inositol 
1,4,5 – trisphosphate (IP3) and diacyglycerol (DAG) (Thibonnier, Berti-Mattera et 
al. 1998, Treschan and Peters 2006). IP3 is a secondary messenger that, upon 
diffusion through the cell, binds to a calcium channel located within the 
endoplasmic reticulum (ER). Upon binding, calcium is released into the cytosol, 
which mediates activation of various further calcium regulated intracellular 
signals. These secondary messengers then act on other enzymes, resulting in 
vasoconstriction (Thibonnier, Berti-Mattera et al. 1998, Treschan and Peters 
2006). V2 receptors act through a slightly different mechanism, stimulating the 
adenylate cyclase pathway, resulting in activation of various protein kinases via 
activation by the secondary messenger cAMP, eventually resulting in aquaporin-
2 transcription and protein formation followed by relocation into the membrane of 
the collecting ducts of the kidneys, allowing water reabsorption (Treschan and 
Peters 2006). This process effectively decreases blood osmolality, while 
increasing plasma volume (Fig.1.3). 
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Figure 1.3: The mechanism of AVP on its two receptors, V1 (Vasopressin 1 
Receptor) and V2 (Vasopressin 2 Receptor) in vascular smooth muscle cells and 
the collecting duct of the kidney. Arginine Vasopressin (AVP), Guanosine 
triphosphate (GTP), phospholipase-C (PLC), inositol 4,5 – bisphosphate (PIP2), 
diacyglycerol (DAG), inositol 1,4,5 – trisphosphate (IP3), endoplasmic reticulum 
(ER), adenylate cyclase (AC), cyclic-AMP (cAMP), phosphokinase A (PKA), 
aquaporin-2 (AQ-2), blood pressure (BP). 
Although the implementation of these two blood pressure regulatory systems 
is essential in maintaining proper blood volume, osmolality, and therefore 
consistent pressure, any over-activation of either sympathetic activity or the RAS 
can result in detrimental cardiovascular complications, of which, the mechanism 
underlying the pathology is still poorly understood. 
1.3 Hypertension 
Hypertension is defined as an abnormally high blood pressure. When this 
abnormality becomes a chronic condition, the individual is exposed to a higher 
risk of further cardiovascular dysfunction, and serious disease that can result in 
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premature death. Not only this, hypertension also incurs a large healthcare 
financial burden of approximately $131 billion per year (Kirkland, Heincelman et 
al. 2018). The AHA’s recent guidelines go further in outlining three different levels 
of hypertension: Elevated (120-129/80 mmHg), stage 1 (systolic anywhere 
between130-139 mmHg or diastolic between 80-89 mmHg), and stage 2 (systolic 
at least 140 mmHg or diastolic at least 90 mmHg) (Whelton, Carey et al. 2018). 
These modifications to the former hypertension guidelines mean that an even 
greater portion of the general population can be diagnosed with some variation or 
differing level of hypertension, and thus require health intervention. Unfortunately, 
there is no one known mechanism underlying hypertensive tendencies. In 
addition, despite the numerous means of treatment currently available, 
hypertension and cardiovascular disease (CVD) remain a major global issue. 
Depending on the cause, hypertension has been split into two subtypes: primary 
(essential) and secondary hypertension. 
Primary hypertension is labelled such when the given hypertension has no 
known cause. Approximately 90% of individuals who are currently diagnosed with 
hypertension have primary hypertension (Carretero and Oparil 2000, Beevers, Lip 
et al. 2001). There is currently no known cause for primary hypertension, given 
the complex etiology of the disease and the differing symptoms and causative 
factors among those afflicted by the condition. However, it is well established that 
many lifestyle factors and behaviors may have a causative relation with 
hypertension and CVD. Some of these factors include smoking, alcohol 
consumption, high salt intake, sedentary lifestyle, and many more generally 
correctable behaviors (Carretero and Oparil 2000, Bolivar 2013). In addition to the 
multitude of environmental and behavioral factors associated with the 
pathogenesis of primary hypertension, many researchers are also searching for a 
common genetic abnormality among individuals with hypertension. 
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The remaining approximately 10% of individuals with hypertension are 
classified under secondary hypertension. Although the prevalence of secondary 
hypertension is much smaller in proportion to the number of primary hypertensive 
individuals, the effects of secondary hypertension are still a major health concern 
worldwide. Secondary hypertension is named so because the hypertension is 
secondary to some other abnormality, such as kidney disease, 
hyperaldosteronism (Douma, Petidis et al. 2008, Puar, Mok et al. 2016), 
obstructive sleep apnea (Pedrosa, Drager et al. 2011), obesity, and many others. 
Although secondary hypertension is generally curable, the underlying 
mechanisms are not always well defined. However, it is important to investigate 
the causes in order to prevent the development of resistant hypertension and 
further cardiac complications, which becomes a risk for individuals who are left 
undiagnosed. 
1.4 Salt Sensitive Hypertension (SSH) 
Over the years, the amount of salt used in meal preparation has drastically 
increased. The Center for Disease Control has established guidelines outlining 
how much salt should be ingested daily. Despite these guidelines, the average 
amount of daily salt intake continues to increase, with average daily intake in the 
United States alone reaching levels greater than 3200 mg/day (Bernstein and 
Willett 2010), which is much more than the amount necessary for normal 
physiological functioning. A correlation between excessive intake of dietary salt 
and an increase in the risk of hypertension has been well established in literature 
from animal and clinical studies (Whelton, Appel et al. 2012, O'Donnell, Mente et 
al. 2015). This susceptibility of certain individuals to an abnormal increase in blood 
pressure following salt intake has been termed “Salt Sensitive Hypertension” 
(SSH). SSH is possibly one of the most prevalent types of hypertension, and 
occurs when an individual’s blood pressure is abnormally increased following salt 
intake. It has been suggested that approximately 51% of hypertensive individuals 
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can be classified as salt-sensitive, while approximately 26% of normotensive 
individuals are also salt-sensitive (Weinberger, Miller et al. 1986, Choi, Park et al. 
2015). Despite the prevalence of this disorder, the pathology and mechanism are 
still poorly understood, despite advancements in hypertension research.  
Numerous reports have focused primarily on the effects of kidney 
dysfunction as a primary cause of SSH. A previously outlined mechanism of 
kidney control of blood pressure regulation was developed by Guyton (Coleman, 
Granger et al. 1971, Guyton 1991), in which it is hypothesized that an increase in 
salt intake, and resultant fluid ingestion, causes an increase in fluid volume within 
the body. This will eventually lead to pressure natriuresis within the kidneys, 
leading to excretion of both salt and water to enable the blood pressure to return 
back to equilibrium (Guyton 1991). This model has been a classic representation 
of what many researchers consider the primary controller of blood pressure 
regulation via the kidneys. Any sort of dysfunction in this system would likely lead 
to chronic hypertension. In a classic experiment performed by Lewis Dahl, salt-
sensitive and salt-resistant rats were subjected to a bilateral nephrectomy 
followed by kidney transplant from either the same, or opposite strain. They were 
then given a normal salt diet. They found that in rats receiving a kidney from a 
salt-sensitive strain, the blood pressure increase was approximately 30 mmHg 
greater than those rats that received a kidney from the salt resistant strain (Dahl, 
Heine et al. 1974). This finding points to a key role of local genetics within the 
kidneys in blood pressure changes in response to salt loading. This finding was 
repeated, and a greater increase in blood pressure in resistant rats receiving 
kidneys from sensitive rats when compared to those who received kidneys from 
other resistant rats was observed (Morgan, DiBona et al. 1990). However, in the 
same study, when given a high salt diet (8%Nacl) as opposed to a normal salt diet 
(0.4%NaCl), salt sensitive rats who received kidney transplants from resistant rats 
as well as fellow salt sensitive rats alike responded with similar increases in blood 
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pressure after the salt loading, indicating that the kidneys alone may not be the 
only regulators of blood pressure. 
Because of this discrepancy, others have argued the potential for the brain 
and the central nervous system as the primary source of dysfunction in SSH. 
Multiple studies have shown that sympathetic outflow is increased following salt 
intake (Leenen, Ruzicka et al. 2002, Fujita and Fujita 2013). As previously 
mentioned, there is also evidence for central action of the RAAS following high 
salt intake, which is specifically mediated through peripheral interactions with 
CVO, and subsequent synaptic transmission to areas such as the PVN, which are 
important in regulation of cardiovascular function (Pan 2004, Wei, Yu et al. 2009, 
Kawano and Masuko 2010).  
Clearly, the etiology and pathogenesis is a rather complex system that 
requires a large deal of attention. Because there is no one clear mechanism 
underlying SSH as of right now, multiple animal models have been utilized to 
mimic SSH in humans, in order to find the molecular connections to SSH. Due to 
various reasons, the primary animal model used in current hypertension research 
is the rat (Pinto, Paul et al. 1998). Two of the most commonly used strains of rats 
used specifically for SSH research are the Dahl Salt-Sensitive (Dahl S) and 
Deoxycorticosterone Acetate (DOCA)-Salt rats, both of which will be the primary 
focus for the remainder of this study.  
1.4.1 Dahl Salt-Sensitive Rat Model 
The Dahl S rat model was developed by researcher Lewis K. Dahl, who has 
come to be known as a significant influence on salt-sensitivity research. During 
his research on the effects of salt ingestion, he noticed that some of the Sprague 
Dawley rats acquired hypertension, while some remained unaffected by the salt 
treatment. He began to selectively inbreed those whose blood pressures 
increased following salt intake with one another, as well as those who did not 
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respond to the salt treatment. Following a few years of breeding, Dahl found that 
he had successfully bred two strains of rats with statistically different reactions in 
blood pressure to a high salt intake, and labelled them sensitive and resistant to 
a high salt intake (Dahl, Heine et al. 1962). This salt sensitive strain eventually 
became known as the Dahl Salt Sensitive rat model, and has since been a major 
model used in salt sensitive hypertension research. The Dahl S rat model is 
generally used as a model for genetic primary hypertension, as this model can 
acquire hypertension even with normal salt intake (Pinto, Paul et al. 1998). Salt 
sensitivity is an additive factor in the adequacy of this model. It is an effective 
model because there is potential for genetic predisposition to salt-sensitivity in the 
90% of individuals who can be classified under primary hypertension. 
1.4.2 DOCA-salt Rat Model 
The DOCA-salt rat model was originally developed in the 1970s. In this 
SSH model, the combination of both DOCA pellet implantation and administration 
of a salt drink solution (~1% NaCl) results in impaired renal handling of sodium, 
eventually leading to hypertension development (Basting and Lazartigues 2017). 
Often, this model is paired with uninephrectomy, which exaggerates the onset of 
hypertension (Basting and Lazartigues 2017). This rat model offers a model for 
primary aldosteronism, a term coined by Jerome Conn to describe excessive 
production of aldosterone from the adrenal glands (Conn 1955). The development 
of hypertension in this model is dependent on the excessive amounts of DOCA, a 
mineralocorticoid and precursor to aldosterone, which results in excessive sodium 
and water reabsorption, as well as potassium excretion in the kidneys (Yemane, 
Busauskas et al. 2010, Basting and Lazartigues 2017). Because increased 
aldosterone levels have been gaining more interest as a primary cause for 
hypertension (Kaplan 2004, Tomaschitz, Pilz et al. 2010), the DOCA model offers 
an adequate model of this pathology. The onset of hypertension with this specific 
model is often observed to occur in stages, with an initial spike in blood pressure 
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within the first couple of days, followed by a more gradual increase and 
maintenance of an elevated blood pressure in the weeks following administration 
(Yemane, Busauskas et al. 2010). This model’s etiology varies greatly from the 
Dahl S rat model, in that it acts as a hypertensive model caused by excessive 
adrenal steroid release and subsequent endocrine dysfunction, as opposed to the 
primary genetic model observed in the Dahl S rat.  
1.5 Neuro-hormonal Mechanisms in Dahl and DOCA-salt Models 
Both rat models offer insight into two differing types of salt sensitive 
hypertension, but both have been observed to show patterns of neural as well as 
central hormonal mechanisms in response to a high salt intake. In the Dahl S 
model, dysfunctional nervous system activity as well as baroreflex dysfunction is 
commonly observed. Studies done on aortic nerve activation, which is part of the 
afferent response to baroreflex activation, and regulation of baroreflex response 
in prehypertensive Dahl S rats fed a low salt diet compared to Dahl Resistant 
(Dahl R) rats found that prehypertensive Dahl S rats showed a significantly lower 
baroreceptor discharge following phenylephrine infusion when compared to 
resistant rats (Gordon and Mark 1984). The same group also found impaired SNA 
activation and subsequent vascular responsiveness increase, resulting in a higher 
TPR in prehypertensive Dahl S rats when compared to Dahl R rats (Gordon and 
Mark 1983).  This relationship indicates that Dahl S rats have a genetic 
predisposition leading to impaired baroreflex sensitivity even before hypertension 
is fully developed. Further evidence showed that, following artificial volume 
expansion of veins through the use of dextran, a high salt diet increased the neural 
inhibitory response and potentiated the dampening of SNA in Dahl R rats, while 
in Dahl S rats fed a high salt diet, cardiopulmonary baroreflex inhibition of SNA 
was decreased, leading to an increase in SNA outflow to the splanchnic nerve 
(Victor, Morgan et al. 1986). The combination of these studies shows that Dahl S 
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rats have a compromised baroreflex and subsequent SNA response to arterial 
pressure changes, most likely due to genetic predispositions. 
Baroreflex dysfunction and excessive SNA have also been observed in the 
DOCA rat model. However, because DOCA hypertension is generally 
characterized by a sharp increase in blood pressure in the first few days, followed 
by a more gradual increase in the following weeks (Yemane, Busauskas et al. 
2010), there is some discrepancy on the magnitude of SNA input on the 
development of hypertension as opposed to the input of hormonal signaling as 
the primary cause of hypertension. In a few studies performed by deChamplain 
(de Champlain, Krakoff et al. 1968, Bouvier and de Champlain 1986) it was 
discovered that DOCA rats, when given 1% NaCl for an extended period of time, 
are found to have reduced norepinephrine binding and storage in the heart, 
meaning that there is more NE in the bloodstream. This was one of the first pieces 
of evidence showing that sympathetic over activity played a role in DOCA-salt 
hypertension during the fully developed phase of hypertension. However, others 
have found that there was no increase in SNA during the early phases of 
hypertension development (Yemane, Busauskas et al. 2010). This is important in 
distinguishing the role that SNA plays in certain portions of hypertension 
development in the DOCA rat. Further research has shown, similar to Dahl S rats, 
that the baroreflex following aortic nerve stimulation is dampened in DOCA rats 
compared to their controls (Takeda, Nakamura et al. 1988, Schenk and McNeill 
1992). 
Along with increased SNA following a HS intake, central RAAS function has 
been extensively observed and studied. The Hypothalamus is an important center 
for RAAS function (McKinley, Allen et al. 2001, Pan 2004), and as previously 
stated, cardiovascular relevant areas such as the PVN have been found to hold a 
large concentration of AT1 receptors, as well as AVP producing neurons (Pan 
2004). Because of this, the brain RAAS has become a major focus in the 
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pathology of Dahl S hypertension. Development of hypertension following a high 
salt diet in Dahl S rats has repeatedly shown evidence of mediation through the 
RAAS within the brain (Teruya, Muratani et al. 1995, Kubo and Hagiwara 2006). 
Further studies have shown that ICV of hypertonic saline elicited a greater 
increase in the blood pressure of Dahl S rats when compared to Dahl R or 
normotensive rats (Huang, Wang et al. 2001, Kubo and Hagiwara 2006). This 
response is thought to be mediated by an increase in cerebrospinal fluid sodium 
concentration, which is sensed by the CVOs and transmitted to cardiovascular 
relevant areas of the brain such as the PVN, activating the RAAS (Yang, Jin et al. 
1992, Huang, Van Vliet et al. 2004). Inhibition of AT1 receptors has also been 
shown to decrease the hypertension normally observed in Dahl S rats (Yang, Jin 
et al. 1992, Gabor and Leenen 2012). A similar role for central RAAS activation 
has also been observed in the DOCA rat model. Following DOCA pellet 
implantation and high salt diet treatment, central RAAS has been shown to be a 
common regulator of the hypertension development seen in this rat model (Basso, 
Ruiz et al. 1981, Itaya, Suzuki et al. 1986, Gutkind, Kurihara et al. 1988). Also, 
similar to the Dahl S model, knockdown of ANGII function following ICV injection 
of captopril, an ACE inhibitor, has been shown to alleviate the elevated blood 
pressure found in DOCA-salt rats, with no effect on normotensive rats (Itaya, 
Suzuki et al. 1986). The combination of these studies in both rat models shows 
the importance of SNA outflow and more importantly, RAAS activity, in the 
pathogenesis of both forms of SSH.  
1.5.1 AVP in Dahl and DOCA Models of Hypertension 
Because of the importance of the RAAS in the development and 
maintenance of elevated blood pressure in both primary and secondary SSH, as 
well as the downstream effects of elevated RAAS activity on SNA outflow, it is 
important to produce new knowledge concerning the dysregulation of central 
hormonal responses following a high salt intake. One of the most important 
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hormones and regulatory factors of blood pressure is AVP. It has become well 
known that an increase in salt intake causes activation of osmoreceptors found in 
the circumventricular organs due to the increased blood osmolarity and mineral 
imbalances. The CVOs then send excitatory projections to the PVN, resulting in 
an increased AVP synthesis within magnocellular neurons of the PVN. This AVP 
is then stored within vesicles at the axon terminals that project from the PVN to 
the neurohypophysis of the pituitary gland. Upon further stimulation, the PVN 
neurons will release AVP directly from these terminals into systemic circulation. 
As previously stated, this increase in AVP within the bloodstream results in 
activation of V1 and V2 receptors, resulting in both vasoconstriction as well as 
water reabsorption in the kidneys. Also, the significance of AVP upregulation in 
both Dahl S and DOCA rats following a high salt challenge has been well 
documented and extensively reviewed (Berecek, Barron et al. 1982, Berecek, 
Murray et al. 1982, Schenk and McNeill 1992, Huber, Fan et al. 2017). Along with 
these studies, microinjection of AVP has been shown to elicit an increase in SNA 
outflow, and antagonism of the V1 receptor within the PVN reduced the SNA 
outflow and blood pressure in salt-loaded rats (Ribeiro, Panizza Hdo et al. 2015). 
Given the increased presence of AVP following salt loading in both neurogenic 
and secondary forms of SSH, the potent regulatory effects of AVP on long term 
blood pressure, the presence of elevated plasma AVP in human hypertension 
patients (Os, Kjeldsen et al. 1986), and the regulatory effect of AVP on SNA 
outflow (Ribeiro, Panizza Hdo et al. 2015), it is logical to assume that AVP over-
activation within the PVN and SON and subsequent elevations in systemic 
circulation following release from the neurohypophysis is critical to the 
development and maintenance of hypertension.  
1.6 Pharmaceutical Interventions 
Because of the importance of RAAS activation and subsequent AVP 
release, many pharmaceuticals used to treat hypertension are aimed towards 
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decreasing RAAS function. Two of the most commonly used pharmaceutical 
interventions are ACE Inhibitors and Angiotensin II Receptor Blockers (Jarari, Rao 
et al. 2015). One study reported that over a five year period, ACE Inhibitors and 
ANGII Receptor Blockers represented approximately 13.3 and 28.3% of 
prescribed anti-hypertensive medications, respectively (Xu, He et al. 2015). In 
practice, these drugs are used to diminish RAAS activity. Although the use of 
these pharmaceutical interventions generally has a positive impact on improper 
blood pressure regulation, studies have shown that an increase in salt intake has 
an opposing action to hypertensive medications (Weinberger, Cohen et al. 1988, 
Calhoun, Jones et al. 2008). In addition, excessive salt intake is believed to have 
a direct impact on the development of resistant hypertension (Calhoun, Jones et 
al. 2008), which is characterized as persistent hypertension despite the use of 3 
or more anti-hypertensive prescription drugs. The prevalence of resistant 
hypertension has been a point of contention, although studies generally observe 
a prevalence in approximately 10-30% of hypertensive individuals (Calhoun, 
Jones et al. 2008, Sim, Bhandari et al. 2013). Although the prevalence among the 
general population is under dispute, primarily due to discrepancy in measurement 
technique and diagnosis, it is generally shown that approximately 5-15% of the 
population exhibit signs of primary aldosteronism (Douma, Petidis et al. 2008), the 
same pathology modelled in the DOCA rat. However, in those individuals with 
resistant hypertension, approximately 20% can also be diagnosed with primary 
aldosteronism (Calhoun, Nishizaka et al. 2002, Eide, Torjesen et al. 2004). In 
order to combat the decreased efficacy of traditional anti-hypertensive 
interventions in resistant individuals, testing and use of anti-aldosterone, 
aldosterone synthase inhibitors, as well as mineralocorticoid receptor antagonists 
has gained recent attention as a possible addition to classic antihypertension drug 
regiments (Oparil and Schmieder 2015), although there is still uncertainty in the 
efficacy of these drugs. Despite new knowledge concerning regulation of blood 
pressure in these hypertensive individuals, an exact mechanism underlying the 
development of salt sensitive hypertension as well as drug resistance has not yet 
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been discovered, nor have the central pathways that regulate RAAS and 
subsequent AVP release following salt intake. 
1.7 Orexin System 
Orexin is a small neuropeptide that was discovered in 1998 by two different 
labs concurrently (de Lecea, Kilduff et al. 1998, Sakurai, Amemiya et al. 1998). 
De Lecea and his colleagues reported that following tag PCR identification of 
multiple mRNA sequences, one was specifically located within the lateral 
hypothalamus (LH). Following cDNA isolation, they found that this prepro-peptide 
encodes the mRNA sequence necessary for the production of two similar proteins, 
specifically in the LH. Following western blot analysis as well as 
immunohistochemistry, they discovered that the protein was indeed localized 
within the LH. De Lecea named these neuropeptides hypocretins, due to their 
position in the Hypothalamus, as well as their similarity to secretin (de Lecea, 
Kilduff et al. 1998). Simultaneous research performed by Sakurai, who was 
searching for potential ligands for receptors whose ligand specificity was still 
unknown, found similar results and named the same proteins Orexin A (OXA) and 
Orexin B (OXB), while their mRNA precursor was named prepro-orexin (Sakurai, 
Amemiya et al. 1998). It was then discovered that the orexins carry out their 
function through interaction with two GPCRs: Orexin Receptor 1 (OX1R) and 
Orexin Receptor 2 (OX2R) (de Lecea, Kilduff et al. 1998, Sakurai, Amemiya et al. 
1998). Despite similar properties, the two receptor types exhibit differing affinities. 
While OX2R can bind with either OXA or OXB with nearly equal affinity between 
subtypes, OX1R has a much higher affinity for OXA (Sakurai, Amemiya et al. 
1998). Sakurai also found that, following ICV injection of OXA or OXB, food intake 
increases in a dose dependent manner, and in a fasted state, prepro-orexin is 
elevated in the LH, indicating an initial role for orexin in appetite (Sakurai, 
Amemiya et al. 1998). 
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Despite the initial idea that orexin primarily controls appetite regulation, it 
was discovered that although orexin is only produced in the LH, its projections 
reach multiple parts of the brain. Axonal projections from LH orexin neurons 
reached important areas such as the hypothalamus, brain stem, limbic system, as 
well as the circumventricular organs (Peyron, Tighe et al. 1998, Nambu, Sakurai 
et al. 1999, Kilduff and Peyron 2000). Because of its extensive projections 
throughout the brain, orexin has been implicated in multiple physiological 
processes such as sleep (Kilduff and Peyron 2000), arousal, appetite (Sakurai, 
Amemiya et al. 1998), and in recent years, regulation of blood pressure and 
sympathetic outflow (Li, Hindmarch et al. 2013, Li and Nattie 2014) (Fig. 1.4). 
 
Figure 1.4: Although orexin production only occurs within neurons located in the 
Lateral Hypothalamus, vast axonal projections to other brain areas allow orexin to 
carry out functions in multiple physiological processes. 
1.7.1 Orexin Effect on Blood Pressure 
Many orexin projections from the LH reach important cardiovascular 
regulatory areas, indicating the potential for orexin action on cardiovascular 
function. Along with the localized orexin neurons far reaching axonal projections, 
many of the areas of innervation coincide with concentration of both OX1R and 
OX2R in these cardiorespiratory areas. Similar to the OX projections, OX1R and 
OX2R mRNA, the precursor to protein formation, are present in areas of the 
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hypothalamus such as the PVN, in Sprague Dawley rats (Trivedi, Yu et al. 1998, 
Li and Nattie 2014), as well as areas of SNA control such as the NTS (Marcus, 
Aschkenasi et al. 2001, Li and Nattie 2014). OX1R and OX2R containing cell 
bodies were also found to be localized in similar areas (Li and Nattie 2014). 
Because of the co-localization of both orexin hypothalamic neuron 
projections and their receptors in major cardiovascular areas of the brain, 
researchers began to study the potential effect of orexin on cardiovascular 
regulation. Samson et al. found that upon ICV administration of OXA and OXB in 
doses of 1 and 5 nmol in normal conscious SD rats, mean arterial pressure 
significantly increased in a dose dependent manner (Samson, Gosnell et al. 
1999). Interestingly, these reported increases in MAP were similar to those elicited 
by ICV injection of 0.1 nmol ANGII under the same conditions (Samson, Gosnell 
et al. 1999). Following the established role of orexin in blood pressure regulation, 
electrophysiological recording showed that administration of OXA and OXB to 
primary neuron cultures of the PVN and RVLM elicited dose dependent 
depolarization of the neurons, a response that was effectively mitigated following 
administration of both OX1R and OX2R antagonists together (Shirasaka, 
Miyahara et al. 2001, Huang, Dai et al. 2010). 
Further studies in rats showed that lack of orexin function following genetic 
prepro-orexin knockout showed that normal rats lacking the prepro-orexin gene 
exhibited a significantly lower resting blood pressure when compared to their 
normotensive wild-type littermates (Schwimmer, Stauss et al. 2010). Similar to 
Samson et al., others found that central administration of both orexins via ICV in 
rats elicited a dose dependent response in not only MAP, but also SNA outflow in 
conscious and anaesthetized animals alike (Shirasaka, Nakazato et al. 1999, Li 
and Nattie 2014). However, since the lateral ventricles allow the orexin to diffuse 
to various brain areas, it makes it hard to pinpoint an exact area of orexin influence 
on SNA outflow and cardiovascular influence. More localized microinjections of 
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OXA in varying doses into the RVLM of SD rats showed a significant increase in 
both SNA as well as MAP (Shahid, Rahman et al. 2012), and this response was 
attenuated following prior administration of an OX1R antagonist (Shahid, Rahman 
et al. 2012). The combination of these studies outlines the extensive role that 
orexin plays, when administered exogenously, in various parts of the brain, 
leading many researchers to believe that orexin system dysfunction may play a 
role in the development and maintenance of hypertension. 
In  BPH/2J mice, a model for essential hypertension, Marques et al. 
(Marques, Campain et al. 2011) found that there is an increase in the gene that 
encodes for orexin within the hypothalamus of these mice when compared to 
controls in both early and established hypertension (Marques, Campain et al. 
2011, Marques, Campain et al. 2011), indicating an intrinsically higher orexin 
activity in the hypothalamus of rat models of primary hypertension. Similar studies 
were then carried out in Spontaneously Hypertensive Rats (SHR), a commonly 
used rat model of primary/neurogenic hypertension that mimics age related 
progression of hypertension development often observed in humans. Li et al. 
found that decreasing orexin activity through oral administration of almorexant, a 
dual orexin receptor antagonist, resulted in a decrease in blood pressure of 
approximately 30mmHg in SHR (Li, Hindmarch et al. 2013). The same study 
showed a large increase in RVLM orexin mRNA expression, although this finding 
did not reach statistical significance (Li, Hindmarch et al. 2013). A subsequent 
study concerned with the specific effects of OX2R found that upon central 
blockade of OX2R function via ICV of an OX2R antagonist as well as 
microinjection into the RVLM of SHR caused a significant decrease in blood 
pressure as well as HR (Lee, Dai et al. 2013), but found a decrease in RVLM 
OX2R expression, in opposition to previous studies. A follow-up study performed 
by the same group showed an increase in hypothalamic OXA and OXB as well as 
RVLM OXA in SHR compared to WKY rats (Lee, Tsai et al. 2015), and also used 
retrograde labelling to discover that SHR have more orexin projections to the 
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RVLM than do WKY rats (Lee, Tsai et al. 2015). Further immunohistochemical 
studies in SHR and normal Wistar Kyoto (WKY) rats showed that SHR showed a 
greater number of orexin expressing neurons in the medial hypothalamus 
compared to WKY rats (Clifford, Dampney et al. 2015), indicating that central 
orexin system overactivation may exacerbate or potentially be a cause for 
neurogenic hypertension observed in the SHR. 
1.7.2 Orexin in Salt Sensitive Hypertension 
Despite the importance of orexin function in the regulation of blood pressure 
as well as in the pathology of hypertensive animal strains such as the BPH/2J 
mouse and SHR, little is known about the implications of orexin in SSH. However, 
there is evidence that the orexin system directly impacts the pathogenesis of SSH. 
It has been extensively reviewed and established that increased SNA as well as 
RAAS activity and subsequent AVP release are essential to the development of 
SSH in both DOCA and Dahl S rats, two models of SSH (de Champlain, Krakoff 
et al. 1968, Berecek, Barron et al. 1982, Gordon and Mark 1983, Gordon and 
Mark 1984, Victor, Morgan et al. 1986, Gutkind, Kurihara et al. 1988, Yang, Jin et 
al. 1992). Exogenous orexin administration in normotensive rats has also been 
shown to cause a drastic increase in blood pressure (Shirasaka, Nakazato et al. 
1999, Li and Nattie 2014), while orexin knockdown via differing mechanisms such 
as oral or central receptor blockade  as well as genetic manipulations of prepro-
orexin activity mitigate the increase in blood pressure  (Schwimmer, Stauss et al. 
2010, Lee, Dai et al. 2013, Li, Hindmarch et al. 2013). In addition, orexin has been 
shown to play a role in the SHR and the development of hypertension.  
Implications for mediation of SSH through the PVN specifically through AVP 
production and secretion have been developed. AVP within the PVN following salt 
loading has been shown to increase blood pressure as well as SNA in SSH 
(Ribeiro, Panizza Hdo et al. 2015). Recent research done on Dahl-S rats fed a HS 
diet has shown that PVN orexin signaling effects the development of hypertension 
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in this salt sensitive model (Huber, Fan et al. 2017). Polymerase Chain Reaction 
(PCR) studies conducted on the PVN of Dahl S rats following a HS diet show that 
mRNA levels of OX1R, OX2R, as well as AVP are all significantly increased in 
Dahl S rats fed a HS diet when compared to their normal salt counterparts (Huber, 
Fan et al. 2017), while immunostaining showed a greater concentration of OX1R 
overexpression in the PVN following HS intake. The same study shows that, in 
primary hypothalamic cultures, AVP mRNA is increased in a dose dependent 
manner following incubation in OXA, and this effect is diminished following 
application of an OX1R antagonist (Huber, Fan et al. 2017). Furthermore, PVN 
OX1R blockade following microinjection decreased the elevated BP normally 
observed in this model (Huber, Fan et al. 2017). This data indicates the essential 
role that orexin, specifically OXA and its interaction with OX1R, plays in the 
maintenance of SSH in the Dahl S rat through modulation of AVP release and 
SNA outflow. 
Despite the implications for orexin system over-activation in the 
pathogenesis of Dahl Salt Sensitive SSH, there is no data addressing its potential 
role for it in other SSH models, specifically the DOCA rat. To date, only one paper 
has been published concerning orexin activity in the DOCA model. However, this 
paper was primarily concerned with diurnal influences on orexin function in DOCA-
salt hypertension (Hernandez, Watkins et al. 2018). In this study, they found that 
OX1R, OX2R, and OXA are increased within the hypothalamus following DOCA 
Salt treatment (Hernandez, Watkins et al. 2018). However, many questions 
remain concerning the role of the orexin system in the DOCA rat model, and other 
salt sensitive models of hypertension. 
1.8 Hypothesis 
In both Dahl S and DOCA rats, AVP is a primary influence on the development 
and maintenance of hypertension (Berecek, Barron et al. 1982, Berecek, Murray 
et al. 1982, Schenk and McNeill 1992, Huber, Fan et al. 2017) . AVP is primarily 
26 
produced within the PVN and SON (Treschan and Peters 2006). The PVN is also 
an area of integration of blood osmolality signals through projections stemming 
from the CVOs (Sunn, McKinley et al. 2003, Pan 2004). Upon HS intake, AVP is 
upregulated in the PVN, an area of major cardiovascular integration within the 
brain. Orexin system over activation has been implicated in primary hypertension 
development in both BPH/2J mice (Marques, Campain et al. 2011) as well as SHR 
(Li, Hindmarch et al. 2013). Ablation of orexin function both centrally and through 
peripheral means has been shown to cause a decrease in the normal elevation of 
BP (Schwimmer, Stauss et al. 2010, Lee, Dai et al. 2013, Li, Hindmarch et al. 
2013). Furthermore, OXA has been shown to directly affect SSH in the Dahl S rat 
model following HS intake, specifically through interaction with the OX1R within 
the PVN, and subsequent release of AVP to the periphery (Huber, Fan et al. 
2017). Lastly, the only study concerned with orexin function in the DOCA rat model 
shows an increase in OXA as well as OX2R within the hypothalamus following 
DOCA-HS treatment. However, this study does not observe the PVN specifically, 
nor does it directly address the effects that the orexin system may play on the 
development of hypertension (Hernandez, Watkins et al. 2018). 
Due to this evidence for orexin function in SSH development, we hypothesize 
that, following DOCA-HS treatment in SD rats, the DOCA pellet induced renal 
sodium and water reabsorption, as well as HS intake will cause PVN OX1R 
signaling to be upregulated via projections of osmoreceptors detecting blood 
osmolality from the CVOs. We also hypothesize that OXA projections to the PVN, 
as well as cell body concentration within the LH will be increased in the DOCA 
rats. Following the interaction between OXA and OX1R in the PVN, we believe an 
increased AVP production and subsequent secretion into peripheral circulation 
will cause an increase in both vasoconstriction as well as water reabsorption 
within the kidneys, resulting in an increased blood volume, and resultant 
hypertension. Furthermore, we hypothesize that PVN microinjection of AAV2-
OX1R-shRNA, a virus causing downregulation of OX1R, will result in a decrease 
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in OX1R activation and AVP release from the PVN, as well as decreased plasma 
AVP and levels. We believe that reducing OX1R function within the PVN of DOCA 
rats will alleviate, at least in part, the development of hypertension in this model. 
A visual representation of our hypothesis can be observed in figure 1.5. The 
results of this study may offer insight into the role of orexin in SSH, and may 
produce evidence offering a new potential pharmaceutical target for hypertension 
treatment. 
 
Figure 1.5: Representative model of the hypothesized mechanism underlying 
orexin control of blood pressure in the DOCA-rat model. Circumventricular organs 
(CVO), lateral hypothalamus (LH), paraventricular nucleus (PVN), orexin A (OXA), 
orexin-1 receptor (OX1R), arginine vasopressin (AVP), adeno-associated virus – 
OX1RshRNA (AAV2-OX1R-shRNA). 
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2 Methods 
2.1 Animals 
All animal breeding was performed and overseen by our lab with the help of 
the Animal Care Facility (ACF). Adult male rats (200-350g) were placed into three 
groups: DOCA-Salt, DOCA-Salt + OX1RshRNA, or untreated control. The DOCA-
Salt group received implantation of a 21-day release DOCA pellet (75mg, 
Innovative Research of America, FL, USA), and saline drinking solution (1% NaCl 
and 0.2% KCl) with normal chow for 21 days. DOCA-Salt + OX1RshRNA rats 
received a PVN microinjection of AAV2-OX1R-shRNA (University of Florida) two 
weeks prior to DOCA and high salt diet administration, identical to the DOCA-Salt 
group. The untreated controls were given sham surgeries, and normal water and 
chow. During the 3 weeks, blood pressure measurements were taken on DOCA-
Salt, DOCA-Salt + OX1RshRNA, and control rats. At the end of the three-week 
DOCA release, rats were placed in metabolic cages for 3 consecutive days. 
Following this, rats were euthanized and used for PCR, immunostaining, plasma, 
and heart weight measurements. The time of euthanization was confined to early 
afternoon, between approximately 2:00-5:00pm, in order to mitigate the chance of 
any variability in measured physiological parameters due to the natural 
fluctuations of orexin activity throughout the day.  All rats were housed at a 
constant temperature and a 12:12 hour light dark cycle, and given their respective 
diets ad libitum. All animal experiments were performed in adherence to protocols 
approved by the Michigan Technological University Institutional Animal Care and 
Use Committee (IACUC). 
2.2 Hypothalamic Paraventricular Nucleus Microinjections 
Prior to any diet or DOCA treatment, DOCA-Salt + OX1RshRNA rats were 
subjected to bilateral PVN microinjection of AAV2-OX1R-shRNA, a viral vector 
that carries a small hairpin RNA that specifically targets the gene encoding for 
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OX1R, effectively knocking down OX1R function. Rats were anaesthetized using 
5% isoflurane for induction, and 2-3% isoflurane exposure for maintenance of 
anesthesia. Following complete anesthesia, rat heads were fixed in a stereotaxic 
frame, so that bregma and lambda were level with one another. Two holes were 
drilled through the skull at coordinates of the PVN so that a single glass 
microinjector pipette could be lowered into the PVN area. The coordinates for the 
PVN (in mm) were as follows: -1.6 caudal to bregma, 0.5-0.7 lateral to the midline, 
and 7.2 deep. Once the microinjector was in place, 200 nl of AAV2-OX1R-shRNA 
was injected bilaterally into the PVN. Approximately 10-12 minutes was taken 
between injections to allow for diffusion of the viral vector. Following injection, the 
wound was sutured, and rats were given a subcutaneous injection of a cocktail 
solution of meloxicam, penicillin, and sterile 0.9% saline the day of injection, as 
well as two days after in accordance with IACUC and ACF standards. DOCA-Salt 
OX1RshRNA rats were given 2 weeks to recover as well as to allow full viral 
expression, before any other procedures were performed. 
2.3 DOCA Pellet Implantation  
DOCA-Salt and DOCA-Salt + OX1RshRNA groups were subjected to 
subcutaneous implantation of a DOCA pellet (75mg, 21-day release, Innovative 
Research of America, FL, USA) prior to beginning the high salt drink treatment. 
Rats were given 5% isoflurane for anesthesia induction followed by 2-3% 
isoflurane to maintain adequate anesthesia during the procedure. A subcutaneous 
incision was made in the retro-scapular region, and the DOCA pellet was placed 
under this layer. The wound was sutured, and rats were given the same post-
operative care as above. However, directly following the procedure, all rats’ 
drinking water was switched to a saline solution (1%NaCl and 0.2%KCl) for the 
remainder of the 21 days. As previously mentioned, DOCA treatment is usually 
paired with uninephrectomy to exacerbate the development of hypertension. 
However, we decided to exclude the kidney removal following a previously 
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established model (Kandlikar and Fink 2011) to obtain a more gradual progression 
of hypertension development that more closely mimics that seen in a humans, as 
well as to eliminate many of the adverse effects that kidney removal has, and their 
causative effects on hypertension (Kandlikar and Fink 2011). This allows us to 
more confidently assume that any results from this study occur because of the 
DOCA pellet and high salt administration and its interaction with the orexin 
system. 
2.4 Blood Pressure Measurement 
A subset of each group was subjected to blood pressure measurement 
during their treatment period using tail plethysmography (Kent Scientific, CT, 
USA). DOCA-Salt, DOCA-Salt +OX1R-shRNA, and control rats were all 
acclimated to the procedure for a week before measurements began through 
everyday blood pressure measurements. Briefly, rats were placed in a plastic 
cylinder with a dark nose-cone, to reduce vision and anxiety. After 10 minutes 
acclimation, the tail cuff apparatus including the occlusion cuff and volume 
pressure recording cuff were placed on the animal for an additional 5-10 minutes. 
Artificial heating was also applied to maintain adequate blood flow to the tail. 
Following this, blood pressure recording began, and 10 acclimation cycles 
followed by 20 measurement cycles were conducted. Following blood pressure 
recording, averages of the 20 measurement cycles were taken and paired with 
their group to obtain a group mean, which was reported. Rats maintained 
acclimation during the 18-day treatment by daily 20-minute sessions in the rat 
holder/tail cuff apparatus for every rat, to reduce variability and anxiety among the 
rats.  
Tail-cuff plethysmography can be attributed to stress-related fluctuations in 
blood pressure, due to confinement in a small cylinder for extended periods of 
time, which may lead to variability of results. However, all necessary precautions 
were taken to mitigate this effect. Namely, acclimation to the cylinders as well as 
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the occlusion/volume pressure recording apparatus began two weeks prior to any 
actual blood pressure recording was performed. Following one week of 
acclimation, blood pressure measurements were taken to identify when the blood 
pressure reached a normotensive level in all treatment groups. Once the blood 
pressure appeared to maintain a consistent, normotensive pressure, the 
experiment was initiated. In addition, blood pressure recording sessions were 
done during the same time every day (12:00-4:00pm), to mitigate circadian 
influences on orexin system function, and thus to alleviate any fluctuations in 
blood pressure that may naturally occur with differential orexin system activity 
throughout the day. Furthermore, during the three weeks of blood pressure 
recording, acclimation was maintained on days when blood pressure 
measurements were not taken by daily exposure to both confinement in the 
cylinder as well as attachment of the occlusion/volume pressure recording 
apparatus for 20 minutes. A diagrammatic representation of this process can be 
observed below (Fig. 2.1): 
 
Figure 2.1: Representation of Tail-Cuff Plethysmography procedural acclimation 
and subsequent BP measurements. Two weeks of acclimation were performed 
before BP measurements were measured, mitigating any stress-induced 
variability caused by the recording. 
2.5 Metabolic Measurements 
During the last 3 days of treatment, DOCA-Salt, DOCA-Salt + OX1RshRNA, 
and control rats were placed in metabolic cages, where food and water intake, as 
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well as urine and fecal output were measured. The first day in the metabolic cages 
was discarded as the results were likely to be affected by the new change of 
environment for the rats. Body weights were also taken weekly for all rats. 
Following euthanization, hearts were removed and weighed, and presented as a 
heart weight to body weight ratio (HW:BW). 
2.6 Real Time PCR and Immunostaining 
Following three weeks of treatment, rats were euthanized and subjected to 
either real time polymerase chain reaction (PCR) analysis to observe mRNA 
levels or immunostaining to visualize protein levels. For PCR, brains were 
removed and immediately flash frozen in liquid nitrogen to mitigate RNAse activity. 
Following flash freezing, all brains were placed into a -80 degrees Celsius freezer, 
where they would remain until needed for mRNA analysis. Upon removal from the 
freezer, the PVN area was punched. RNA isolation was performed using RNeasy 
plus Mini kits (Qiagen, CA, USA) following packaged instructions. Following 
isolation, the RNA was converted to complementary DNA (cDNA) using iScript 
cDNA synthesis kits (Bio-Rad), and cDNA was used as a template for real time 
PCR, which was performed to analyze mRNA levels of OXA, OX1R, and AVP 
using gene specific Taqman primers and probes. The results were normalized to 
mRNA expression of the housekeeping gene, GAPDH. 
Immunostaining was used to analyze OX1R, OXA, and AVP protein 
expression within the PVN, as well as OXA within the lateral hypothalamus. 20-
μm coronal brain sections containing the PVN or LH using the following 
procedure. Rats were anesthetized under heavy isoflurane. Once under deep 
anesthesia, cold phosphate buffer saline (1xPBS) followed by 4% 
paraformaldehyde (PFA) in 1xPBS was used to transcardially perfuse the animal. 
Following perfusion, the brain was removed and kept in 4% PFA overnight in 4°C. 
The next day, the brains were transferred and kept at 4°C in 30% sucrose until 
they sank to the bottom. They were then cut in 20-μm coronal sections using a 
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cryostat. Areas containing the PVN area as well as the LH were then subjected to 
immunostaining. Following wash in 1xPBS 3 times for 10 minutes each, brain 
sections were incubated with either rabbit anti-OX1R antibody (Alomon 
Laboratories, Jerusalem, Israel, 1:300 dilution), rabbit anti-AVP antibody (1:400 
dilution), or mouse anti-OXA antibody (1:300 dilution) in PBS containing 0.5% 
Triton X-100 and 5% horse serum for 4 days at 4°C. Following this incubation and 
1xPBS washing, they were incubated overnight in secondary antibodies Alexa 
fluor 488 goat anti rabbit IgG (1:500), Alexa fluor 594 goat anti rabbit IgG (1:500), 
or Alexa fluor 594 donkey anti mouse IgG (1:500). Images representing 
immunofluorescence were taken with a Leica DMIL microscope. 
2.7 Plasma AVP and CSF Orexin A ELISA Testing 
Rats were placed under heavy anesthesia using 5% isoflurane. They were 
then decapitated, and blood was collected in tubes coated with 5.4mg EDTA (BD 
Vacutainer, NJ, USA) to collect plasma for measurement. These tubes were then 
centrifuged at 4°C using an Eppendorf 5804 R Centrifuge at 1300 RPM for 35 
minutes. The supernatant was extracted, and stored in -80ºC until use. ELISA 
testing was used to analyze both plasma concentration of AVP (Arg8-Vasopressin 
Kit, Enzo Life Sciences, NY, USA) as well as cerebrospinal fluid Orexin A 
concentrations (Orexin-A ELISA, Fujuifilm, Tokyo, Japan) using the 
manufacturer’s provided instructions. 
2.8 Intracerebroventricular Injections 
Male adult SD rats were subjected to ICV injections of either saline control 
or OXA (Sigma Aldrich, MO, USA). Rats were anesthetized under 5% isoflurane, 
and maintained at 2-3% isoflurane. Rats were set up in a stereotaxic frame as in 
PVN injections. A hole was made in the skull to allow penetration of a Hamilton 
syringe into the left lateral ventricle. The coordinates for injection were as follows: 
-0.8 mm caudal to bregma, 1.6 mm lateral to the midline, and 3.6 mm deep. For 
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the ICV injection, saline (0.9%) control was injected at a volume of 4μl over the 
course of 4 minutes on only one side. Rats that received OXA (2nmol) also 
received 4μl over the course of 4 minutes. Approximately 10 minutes following 
injection brain and plasma were collected and used for PCR as well as ELISA 
testing. 
2.9 Data Collection and Analysis 
All rats subjected to PFA perfusion and subsequent immunostaining were 
unable to be used for any physiological analysis other than protein 
immunofluorescence staining. However, all other animals subjected to brain, 
blood, and CSF collection were utilized for multiple tests, including PCR and 
ELISA. Because of the overlap, and the multiple utilizations of one sample for 
various tests, some discrepancies in sample size may be present. In general, an 
arbitrary sample size of 4-5, which is normally observed in other experiments 
performed in rodent models, was chosen as a goal for each treatment group, 
although this was not always the case due to the additional accumulation of new 
results on the same physiological parameters tested throughout the progression 
of the project. Furthermore, results from multiple experiments (Fig. 2.2) were 
combined over the course of the project when the same parameters were 
measured. However, to simplify the number of rats subjected to immunostaining 
as well PCR and ELISA, Fig. 2.2 shows a representation of the number of rats 
subjected to each treatment, and what physiological parameters were eventually 
measured, excluding the six rats used during the ICV injection. In addition, all 
animals that were lost during surgery, before any measurements were taken, were 
not recorded, and were simply replaced, eliminating any effect on sample size.  
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Figure 2.2: Representative diagram showing the number of rats from each 
experiment (Exp. 1-5) during the project and what physiological analysis was 
performed on each. Note: Only rats during experiment 5 were subjected to blood 
pressure measurements over the course of the three-week treatment. 
All data is expressed as Mean ± SEM unless otherwise noted. Individual blood 
pressure means were observed, and then combined with other subjects within 
their given treatment group to find a group mean and SEM. To test significance 
unpaired one-tailed and two-tailed T-tests, as well as One-way ANOVA testing 
was performed using Graphpad Prism-6 software. If significance was found using 
the ANOVA, a Tukey HSD test was performed. For blood pressure and heart rate 
data, a two-way ordinary ANOVA was performed, and if significance was found, 
a Tukey multiple comparison test was performed between time points. All values 
with a P<0.05 were considered significant. 
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3 Results 
The classic model for DOCA-salt hypertension generally utilizes kidney 
removal (uninephrectomy) to exacerbate the development and severity of 
hypertension in the animal. However, for our model, we chose to omit the kidney 
removal, allowing a more gradual and moderate increase in blood pressure, which 
more closely mimics hypertension development observed in humans. However, 
kidney removal affects renin levels, and thus AVP secretion and RAAS activity. It 
has been extensively shown that AVP secretion is essential to hypertension 
development in the classical DOCA-salt model, so we first assessed whether our 
model would produce adequate central AVP production, as well as parallel 
increases in OX1R levels. Furthermore, we wished to observe whether central 
AVP increases correlated with peripheral secretion in the plasma, using this as 
evidence of downstream AVP activity on vasoconstriction and renal water 
reabsorption. Lastly, we assessed metabolic measurements due to AVP and 
orexin regulation of metabolic activity. 
3.1 DOCA-salt Treatment Increases PVN AVP and OX1R 
Expression 
The efficacy of our modified DOCA-salt model in producing a similar 
increase in central AVP production as the classical uninephrectomized DOCA-salt 
rats was tested following 3-weeks of DOCA-salt treatment. Following treatment, 
real time PCR was used to analyze PVN AVP mRNA expression, and 
immunostaining was used to visualize AVP protein expression within the PVN. 
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Figure 3.1: PVN AVP mRNA expression following 3-weeks of DOCA-salt 
treatment. DOCA-salt (n=9) treatment significantly increased PVN AVP mRNA 
expression compared to control rats (n=8). *P<0.05 using an unpaired two-tailed 
T-test.
A significant increase in PVN AVP mRNA expression was observed in 
DOCA-salt rats (n=9) when compared to control rats (n=8) (control: 1±0.319 vs. 
DOCA-salt: 3.142±0.7914, P<0.05), which was to be expected, as it is generally 
observed in the classic DOCA-salt model (Fig. 3.1). Further immunostaining 
assessment also showed a large increase in PVN AVP protein expression when 
compared to control rats (Fig. 3.2). The combination of these results shows that 
DOCA-salt treatment results in significantly increased AVP production within the 
PVN, inferring that overproduction of AVP is still present in our modified DOCA-
salt model. 
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Figure 3.2: Representative immunostaining images of AVP protein expression in 
control (left) and DOCA-salt (right) rats. 
After observing an increase in central AVP production within the PVN of 
DOCA-salt rats, we then analyzed whether an increase in OX1R receptor 
expression occurs in parallel with PVN AVP increases following DOCA-salt 
treatment. To assess this, PCR and immunostaining were once again utilized to 
assess PVN mRNA and protein expression. PCR results indicated a significant 
increase of approximately 23% in PVN OX1R mRNA levels following DOCA-salt 
treatment (n=4) compared to control (n=3) (control: 1.00±0.049 vs. DOCA-salt: 
1.231±0.08; P<0.05) (Fig. 3.3). 
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Figure 3.3: PVN OX1R mRNA expression following 3-weeks of DOCA-salt 
treatment. DOCA-salt (n=4) treatment significantly increased PVN OX1R mRNA 
expression compared to control rats (n=3). *P<0.05 using an unpaired one-tail T-
test. 
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To affirm whether increased OX1R mRNA levels resulted in increased OX1R 
protein expression, immunostaining was performed. Immunostaining images 
show a large increase in OX1R expression and concentration in the PVN area 
(Fig. 3.4). The significant increase in both AVP as well as PVN OX1R expression 
is indicative of a relationship between the parallel increase observed and DOCA-
salt treatment. 
Figure 3.4: Representative immunostaining images showing expression of the 
orexin-1 receptor (OX1R) in the PVN in both control (left) and DOCA-salt (right) 
rats. Third ventricle (3V). 
3.2 DOCA-salt Treatment Increases Plasma AVP Concentration 
The DOCA-salt model is generally characterized by elevated plasma AVP 
concentrations. Since an increase in PVN AVP expression was expressed, we 
used ELISA to test plasma AVP concentrations in control rats as well as DOCA-
salt treated rats, to observe whether the central increase in AVP production results 
in an increase in peripheral circulation. Following 3 weeks of treatment, DOCA-
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salt treated rats (n=8) showed a significantly higher plasma AVP concentration 
when compared to control rats (n=4) (control: 9.04±2.57 vs. DOCA-salt: 
37.94±8.66 pg/ml; P<0.05) (Fig. 3.5). This result agrees with previous 
observations showing similar increases in peripheral AVP levels (Lariviere, St-
Louis et al. 1988, Saravia, Grillo et al. 1999).  
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Figure 3.5: Plasma AVP concentrations (pg/ml) in control (n=4) and DOCA-HS 
(n=8) treatment groups. DOCA-salt treatment resulted in a significant increase in 
plasma AVP concentration. *P<0.05 vs. control using an unpaired two-tail T-test. 
3.3 DOCA-salt Treatment Effects on Metabolism 
Following 3 weeks of treatment, all rats were placed in metabolic cages for 
72 hours to assess urine and fecal output, food and water intake, and body weight. 
Following 24-48 hours of acclimation to the environment, food intake (g), fecal 
output (g), water intake (mL), as well as urine output (mL) were measured over a 
24-hour period to analyze the effects that our modified DOCA-salt model elicited
on metabolism.
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Figure 3.6: 24-hour metabolic data of control (n=4) and DOCA-salt (n=3) treated 
rats following 3-weeks of treatment. DOCA-salt treatment significantly reduced 
food intake when compared to control rats, but significantly increased water 
intake, fecal output, and urine output when compared to control rats. *P<0.05, 
**P<0.01, ****P<0.0001 vs. control using an unpaired two-tailed T-test. 
Following 3-weeks of treatment, DOCA-salt rats (n=3) showed significant 
differences in metabolism when compared to controls (n=4). DOCA-salt treatment 
resulted in a significant decrease in food intake (control: 26.39±1.45 vs. DOCA-
salt: 18.91±2.42 g, P<0.05), as well as a significant increase in fecal output 
(control: 4.26±1.15 vs. DOCA-salt: 1.41±0.38 g, P<0.05) when compared to 
control rats (n=4) (Fig. 3.6). Also, DOCA-salt treatment resulted in a significant 
increase in water intake (control: 22.72±2.719 vs. DOCA-salt: 176.7±29.24 ml, 
P<0.01) and urine output (control: 6.8±0.578 vs. DOCA-salt: 126.1±5.346 ml, 
P<0.0001) compared to controls (Fig. 3.6). A decrease in weight gain was also 
observed following DOCA-salt (n=7) treatment when compared to control rats 
(n=6) (control: 129±6.429 vs. DOCA-salt: 81.71±8.626 g, P<0.01) (Fig. 3.7). 
42 
C o
n t
ro
l 
D O
C
A -
H S
0
5 0
1 0 0
1 5 0
W e ig h t G a in
C
h
a
n
g
e
 i
n
 B
o
d
y
 W
e
ig
h
t 
(g
)
**
Figure 3.7: Difference in body weight from beginning and end of treatment. 
DOCA-salt (n=7) treatment results in a significant attenuation of weight gain 
compared to control rats (n=6). **P<0.01 using an unpaired two-tailed T-test. 
3.4 Central Orexin-A Administration Increases Plasma AVP 
Concentration in Normal SD rats 
Following affirmation that plasma AVP levels are indeed increased 
following DOCA-salt treatment, we then wished to find out whether orexin system 
activity was a primary regulator of AVP release peripherally. Previous research 
done in our lab showed a significant increase in PVN AVP protein expression 
following acute OXA ICV injection in normal rats (Huber, Fan et al. 2017). Because 
centrally administered OXA results in increased PVN production of AVP, we then 
tested whether central administration of OXA causes a parallel increase in AVP 
secretion into peripheral circulation. To test this, six rats were given ICV injections 
of either 0.9% saline (n=3) or OXA (2nmol) (n=3). Ten minutes following injection, 
animals were sacrificed and plasma was collected for AVP ELISA measurement. 
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Figure 3.8: Plasma AVP concentrations (pg/ml) following ICV injection of saline 
(0.9%) (n=3) or OXA (2nmol) (n=3). OXA ICV elicited a noticeable increase in 
AVP plasma levels, although this did not reach significance (P=0.08) when using 
an unpaired one-tailed T-test. 
Although significance was not reached (P=0.08), an obvious trend towards 
significance was observed as OXA ICV (n=3) elicited an increase in plasma AVP 
levels when compared to saline controls (n=3) (saline: 46.86±8.73 vs. OXA: 
82.69±19.23 pg/ml) (Fig. 3.8). This relationship indicates that acute central 
injection of the OX1R agonist, OXA, results in an increase in peripheral AVP 
circulation, leading us to believe that long-term orexin system over-activation may 
lead to a chronic increase in plasma AVP often observed in the DOCA-salt model. 
All data collected has shown that DOCA-salt treatment increases not only 
central and peripheral AVP expression, but also increases PVN OX1R 
expression. Furthermore, acute injection of the OX1R agonist, OXA, results in a 
near significant increase in peripheral AVP in the plasma. However, these results 
do not prove an interaction between orexin system activation and regulation of 
AVP release in the DOCA-salt model, nor do they give any insight into long-term 
orexin mediated AVP release. To analyze the chronic impact of the orexin system 
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on DOCA-salt hypertension, rats were given bilateral PVN injections of AAV2-
OX1R-shRNA, a viral vector carrying a short hairpin RNA that specifically targets 
and knocks down the gene that encodes for OX1R, two-weeks prior to DOCA-salt 
treatment. 
3.5 Lateral Hypothalamic OXA Neuron Expression Remains 
Elevated Following Chronic PVN OX1R Knockdown 
To investigate the relative concentration of protein expression of orexin 
related proteins, immunostaining was performed, which allows visualization of 
target protein expression within the relevant brain regions. 
We first chose to investigate whether orexin producing neuron expression 
within the LH, as well as axonal projection density in the PVN is increased 
following DOCA-salt treatment. To test this, following three weeks of DOCA-salt 
treatment, animals were transcardially perfused with cold 4% PFA, and brains 
were removed. Coronal sections of the brain were then taken in areas that 
corresponded to positions of the LH and PVN. These sections were subjected to 
immunostaining, specifically targeting OXA. Following DOCA-salt treatment, it 
appears that OXA expressing cell bodies within the LH were increased when 
compared to SD untreated control rats (Fig. 3.9A). Interestingly, there did not 
appear to be any major differences between PVN axonal projections in the DOCA-
salt rats when compared to the controls (Fig. 3.9B). 
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Figure 3.9: Representative immunostaining images showing expression of 
orexin-A (OXA) within (A) the lateral hypothalamus (LH) as well as (B) the 
Paraventricular Nucleus of the Hypothalamus. The first column shows untreated 
control rats. The second column shows DOCA pellet (75mg, 21-day release) and 
high salt (1%NaCl/0.2%KCl) treated rats (DOCA-HS). The third column shows 
rats that received prior orexin-1 receptor viral antagonist bilateral microinjection 
into the PVN two weeks prior to the DOCA-salt treatment (OX1RshRNA). 
A similar increase in OXA cell body expression within the LH can be 
observed in rats that received AAV2-OX1R-shRNA (OX1R antagonist) prior to 
DOCA-salt treatment (Fig. 3.9A) when compared to untreated controls. However, 
in contrast to the DOCA-salt rats, PVN OXA axonal projections from the LH 
appear to have a greater expression and density in rats who received bilateral 
PVN OX1R antagonist injections (Fig. 3.9B). 
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3.6 Chronic PVN OX1R Knockdown Decreases OX1R 
Expression 
The above results show that DOCA-HS treatment increases OXA neuron 
cell body immunoreactivity, indicating an intrinsic increase in LH orexin production 
and activity. However, we also wanted to see how the treatment would affect PVN 
OX1R, the receptor for OXA, expression and immunoreactivity.  
PCR analysis of the PVN area showed that OX1R mRNA expression is 
increased by approximately 35% following DOCA-salt treatment (1.348±0.109; 
n=10) when compared to control rats (1±0.087; n=7) (Fig. 3.10). However, PVN 
OX1R knockdown significantly decreases OX1R mRNA expression 
(0.8537±0.072; n=5) when compared to DOCA-salt treated rats (P<0.05) (Fig. 
3.10), indicating that viral vector application to the PVN effectively reduces OX1R 
function within the PVN to normal levels. 
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Figure 3.10: PVN OX1R mRNA levels of expression normalized to GAPDH 
expression. DOCA-salt treated rats (n=10) show an increase of approximately 
34% PVN OX1R expression compared to control rats (n=7), and this increase is 
significantly reduced following OX1R knockdown (n=5) (P<0.05) using a one-way 
ANOVA and Tukey post-hoc analysis.  
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Immunostaining analysis showed an increase in OX1R expression within 
the PVN of DOCA-salt rats when compared to control rats (Fig. 3.11), in 
agreement with our previous results (Fig. 3.4). We then wished to test whether 
bilateral injection of AAV2-OX1R-shRNA into the PVN of DOCA-salt rats reduces 
the density of OX1R within the PVN. As shown above, OX1R expression is 
increased in the DOCA-salt rats when compared to the controls (Fig 3.4). 
However, following injection of AAV2-OX1R-shRNA prior to DOCA-salt treatment, 
OX1R expression is successfully knocked down in the PVN (Fig 3.11), as 
evidenced by the lack of co-localization of OX1R and GFP expressing neurons. 
Figure 3.11: Representative immunostaining images showing orexin-1 receptor 
(OX1R) expression within the PVN of control (far left), DOCA-salt (middle left), 
and DOCA-salt rats injected with AAV2-OX1R-shRNA into the PVN (middle right). 
The farthest image on the right shows co-immunostaining of both OX1R as well 
as green fluorescence protein (GFP) that is intrinsically present in the viral vector 
used for OX1R knockdown. The lack of OX1R expression in areas of high GFP 
expression is indicative of successful OX1R knockdown following viral vector 
injection. 
3.7 Chronic PVN OX1R Knockdown Reduces Central AVP 
Production 
The above combination of results showing an increase in PVN OX1R mRNA 
and protein levels, as well as an increase in LH OXA protein expression indicate 
over activation of the orexin system as a key component in the development of 
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DOCA-salt hypertension. To test whether the decrease in OX1R function following 
viral injection resulted in a parallel decrease in central AVP mRNA expression, 
PVN tissue was punched and subjected to PCR assessment. PVN AVP mRNA 
levels were significantly increased following DOCA-salt treatment when compared 
to controls (control: 1±0.319 vs. DOCA-salt: 3.142±0.791, P<0.05) (Fig. 3.12). 
However, following chronic knockdown of PVN OX1R, AVP mRNA levels were 
significantly decreased when compared to DOCA-salt (DOCA-salt: 3.142±0.791 
vs. DOCA-OX1RshRNA: 0.644±0.281, P<0.05) (Fig. 3.12). There was no 
significant difference observed between control and DOCA-OX1RshRNA groups. 
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Figure 3.12: PVN AVP mRNA levels of expression normalized to GAPDH 
expression. DOCA-salt treated rats (n=10) have a significant increase in PVN AVP 
expression when compared to control (n=7) (*P<0.05) as well as when compared 
to DOCA-HS/OX1RshRNA (n=5) (*P<0.05) rats using a one-way ANOVA and 
Tukey post-hoc analysis. 
Knockdown of OX1R results in a decrease in mRNA levels of OX1R as well 
as AVP within the PVN, along with subsequent OX1R protein 
immunofluorescence, indicating that the orexin system over activation can be 
corrected via bilateral microinjection of an OX1R antagonist into the PVN of 
DOCA-salt rats. We then wished to elucidate whether chronic OX1R knockdown 
would result in a subsequent decrease in AVP protein expression within the PVN. 
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Figure 3.13: Representative immunostaining images showing arginine 
vasopressin (AVP) expression within the PVN of control (far left), DOCA-salt 
(middle left), and DOCA-salt rats injected with AAV2-OX1R-shRNA into the PVN 
(middle right). The farthest image on the right shows co-immunostaining of both 
AVP as well as green fluorescence protein (GFP) that is present in the viral vector 
used for OX1R knockdown. The lack of AVP expression in areas where GFP is 
high is indicative of successful decrease in AVP expression following OX1R 
knockdown. 
AVP expression within the PVN was greatly increased in DOCA-salt rats 
compared to control rats, as can be observed by increased density and brightness 
of AVP expression following immunostaining (Fig. 3.13). However, prior 
microinjection of an OX1R antagonist (AAV2-OX1R-shRNA) reduces the 
increased AVP expression that is normally seen in DOCA-salt rats (Fig. 3.13). 
This indicates strong evidence for orexin system modulation of AVP production 
and subsequent release following a DOCA-salt treatment. 
3.8 Chronic PVN OX1R Knockdown Decreases Plasma AVP 
Concentration 
After observing increases in mRNA and protein expression of both OX1R as 
well as AVP within the PVN of DOCA-salt rats, and the attenuation of this following 
chronic OX1R knockdown, we began to investigate peripheral circulation of AVP. 
We wished to observe whether central OX1R knockdown results in lowered 
plasma AVP levels. We hypothesized that OX1R PVN knockdown would 
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significantly decrease plasma AVP concentrations when compared to DOCA-salt 
treated rats. 
To test the chronic effects of orexin system modulation of peripheral AVP 
secretion, following three weeks of DOCA-salt treatment, plasma as well as CSF 
were collected as previously outlined, and subjected to AVP and OXA ELISA 
testing. 
Figure 3.14: (A) Cerebrospinal fluid OXA concentration in control (n=5), DOCA-
HS (n=3), and DOCA HS-OX1RshRNA rats (n=3). DOCA-salt treatment reduced 
circulating CSF OXA, and this is mitigated by PVN OX1R knockdown, although 
this relationship did not reach significance (P=0.37). (B) Plasma AVP 
concentration (pg/ml) in control (n=3), DOCA-salt (n=6), and DOCA HS-
OX1RshRNA (n=3) rats. DOCA-salt treated rats show an increased AVP plasma 
concentration, but this did not reach significance (P=0.09). However, following 
two-tailed t-test evaluation, we observed a significant decrease in plasma AVP 
following chronic OX1R knockdown (*P<0.05) when compared to DOCA-salt 
treatment using a one-way ANOVA and Tukey post-hoc analysis. 
Interestingly, we observed an apparent decrease in CSF OXA 
concentration in DOCA-salt treated rats (47.04±12.5 pg/ml; n=3) when compared 
to both control (93.62±20.25 pg/ml; n=5) and DOCA-salt/OX1RshRNA 
(104.6±44.34 pg/ml; n=3) rats (Fig. 3.14A). Although this observation did not 
reach significance (P=0.37), further explanation of this result can be found in the 
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discussion. Furthermore, there is a strong trend towards significance (P=0.09) in 
the long-term increase of plasma AVP in DOCA-salt (258.9±19.5 pg/ml; n=5) 
when compared to control (181.7±43.6 pg/ml; n=3) and DOCA-salt/OX1RshRNA 
(167.2±29.8 pg/ml; n=3) (Fig. 3.14B). However, because the trend was very 
strong, we decided to determine whether OX1R PVN knockdown significantly 
effects plasma AVP levels when compared only to DOCA-salt treated rats. 
Following two-tailed t-test evaluation of DOCA-salt and DOCA-HS/OX1RshRNA 
rats, we found that the OX1RshRNA treatment significantly decreased plasma 
AVP when compared solely to DOCA-salt treatment (P=0.035) (Fig. 3.14B). This 
trend is indicative of long-term modulation of plasma AVP secretion by central 
orexin system functioning. 
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3.9 Chronic PVN OX1R Knockdown Effects on Metabolism 
Figure 3.15: 24-hour metabolic analysis of food and water intake as well as urine 
and fecal output in all rats at the end of their respective treatments. DOCA-salt 
treatment results in a significant increase in both water intake and urine output 
when compared to control rats, and chronic knockdown of OX1R does not appear 
to alleviate this effect. Control (n=4), DOCA-salt (n=5), DOCA+OX1RshRNA 
(n=6). *P<0.05 vs. control, **P<0.01 vs. control using a one-way ANOVA and 
Tukey post-hoc analysis. 
Metabolic measurements were taken following 3-weeks of DOCA-salt 
treatment. Over the course of 24-hours at the end of the treatment, DOCA-salt 
rats (n=5) experienced a significant increase in water intake when compared to 
control rats (n=4) (DOCA-salt: 141.3±28.89 vs. control: 22.72±2.72mL, P<0.05), 
as well as increased urine output (DOCA-salt: 101±17.81 vs. control: 
6.8±0.578mL, P<0.01) (Fig. 3.15). This significant increase was also observed in 
DOCA-OX1RshRNA rat (n=6) water intake (DOCA-OX1RshRNA: 122.1±24.43 vs 
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control: 22.72±2.72mL, P<0.05) and urine output (DOCA-OX1RshRNA: 
79.58±11.3 vs. control: 6.8±0.578mL, P<0.01) when compared to control rats 
(Fig. 3.15). There was no observed statistical difference between DOCA-salt and 
DOCA-OX1RshRNA water intake and urine output. Similarly, no significant 
differences were observed in food intake (control: 26.39±1.455 vs. DOCA-salt: 
21.62±2.129 vs. DOCA-OX1RshRNA: 24.32±0.699g, P=0.1) or fecal output 
(control: 1.41±0.378 vs. DOCA-salt: 3.48±0.813 vs. DOCA-OX1RshRNA: 
2.76±0.295g, P=0.07) between any of the groups (Fig. 3.15). 
During the three-week treatment, body weight was taken once per week in 
control (n=10), DOCA-salt (n=17), as well as DOCA+OX1RshRNA (n=5) groups. 
We then assessed the difference in body weight from the beginning of treatment 
and the day of euthanization. This allowed us to assess the affect that DOCA-salt 
as well as DOCA-salt + OX1RshRNA may have on weight gain. 
C o
n t
ro
l
D O
C
A  
H S
D O
C
A  
H S
/
O
X 1
R s
h R
N A
0
5 0
1 0 0
1 5 0
W e ig h t G a in
C
h
a
n
g
e
 i
n
 B
o
d
y
 W
e
ig
h
t 
(g
)
**
*
Figure 3.16: Graph of the difference in weight between the beginning and end of 
treatment in all groups. A significant dampening of weight gain is observed in both 
DOCA-salt (n=17) as well as DOCA+OX1RshRNA (n=5) rats compared to 
untreated controls (n=10). *P<0.05, and **P<0.01 vs. control using a one-way 
ANOVA and Tukey post-hoc analysis. 
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DOCA-Salt treatment caused a significantly lower weight gain over the 
course of three weeks when compared to the control rats (control: 86±16.34 vs. 
DOCA-salt: 53.06±7.54 g, P<0.01) (Fig. 3.16). DOCA-OX1RshRNA rats also had 
a significantly lower weight gain than control rats (control: 86±16.34 vs. DOCA-
OX1RshRNA: 37.1±5.26 g, P<0.05) (Fig. 3.16). Although there was no significant 
difference between DOCA-salt and DOCA+OX1RshRNA rats, there appears to 
be a slight trend towards a greater attenuation of weight gain in OX1R knockdown 
rats (Fig. 3.16). 
3.10  Cardiac Hypertrophy is Partially Attenuated by PVN OX1R 
Knockdown 
Cardiac hypertrophy is often associated with hypertension development, and 
may cause further cardiovascular dysfunction. To test cardiac hypertrophy, rat 
hearts were removed and weighed following animal euthanization. Cardiac 
hypertrophy was quantified by measuring the heart weight to body weight ratio 
(HW:BW), which allows assessment of the percentage of the animal body weight 
that is accounted for by the heart. 
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Figure 3.17: Quantification of cardiac hypertrophy through measurement of heart 
weight to body weight ratio (HW:BW). DOCA-salt (n=13) showed a significantly 
increased heart size when compared to control rats (n=8). DOCA-OX1RshRNA 
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(n=5) showed a slight decrease in HW:BW compared to DOCA-salt rats, but this 
trend did not reach significance using a one-way ANOVA and Tukey post-hoc 
analysis. *P<0.01 vs. control. 
DOCA-salt rats (n=13) had a significantly higher HW:BW when compared 
to control rats (n=8) (control: 0.311±0.011 vs. DOCA-salt: 0.402±0.017%, 
P<0.01). DOCA-OX1RshRNA rats (DOCA-OX1RshRNA: 0.352±0.019%) showed 
no significant differences when compared to either control or DOCA-salt rats, 
although there is a slight decrease when compared to DOCA-Salt rats (DOCA-
OX1RshRNA: 0.352±0.019 vs. DOCA-salt: 0.402±0.017%, P>0.05) (Fig. 3.17), 
indicating that OX1R knockdown may slightly alleviate the cardiac hypertrophy 
observed in DOCA-salt hypertension, even though significance was not reached. 
3.11  PVN OX1R Knockdown Attenuates Elevation of Blood 
Pressure in DOCA-salt Rats 
Because over activation of the orexin system in the PVN is observed in the 
DOCA-salt model, and largely attenuated following PVN OX1R knockdown, as 
well as AVP, we decided to analyze whether OX1R PVN knockdown alleviated 
DOCA-salt hypertension development. Using tail-cuff plethysmography, rats were 
acclimated to blood pressure measurement for one week prior to the start of the 
study. Control (n=5), DOCA-salt (n=4), and DOCA-OX1RshRNA (n=4) were all 
from the same litter and measurements were performed during the same time. 
The last day of the acclimation period was used as the baseline blood pressure 
measurement. Following acclimation, blood pressure and heart rate were taken 
over the course of 18 days. We did not perform BP measurements the last 3 days 
of treatment because the rats were in metabolic cages at this time, and transport 
to and from the cages to take BP measurements may have skewed the 
recordings. Also, to keep the rats acclimated, they were placed in the holders 
every day for 20 minutes on days when recordings were not measured. This was 
done to lower anxiety, and keep results consistent. Two rats, one from the DOCA-
salt and one from the DOCA-OX1RshRNA, were removed from blood pressure 
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and heart rate measurements due to illness resulting in lack of food and water 
intake, as well as physical deformity and body weight loss, all of which are factors 
that may affect AVP, orexin activity, among other physiological parameters. 
Because of these physiological implications, they were excluded from 
measurement. 
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Figure 3.18: Mean arterial pressure (MAP) measurements over the course of 18 
days as measured by tail-cuff plethysmography comparing control (n=5), DOCA-
salt (n=4), and DOCA+OX1RshRNA (n=4) rats. Results are reported as group 
averages during each measurement day. Dotted line indicates when DOCA-pellet 
and HS diet were administered. *P<0.05, **P<0.001 vs. control. #P<0.05, 
##P<0.01 vs. DOCA-salt using a two-way ANOVA and Tukey post-hoc analysis. 
Approximately one week following DOCA implantation, the DOCA-salt 
group MAP raised to a point significantly greater than the control group (P<0.05) 
(Fig. 3.18). This significant increase was maintained throughout treatment for the 
most part. Interestingly, PVN OX1R knockdown resulted in a significant, and 
sustained decrease in MAP when compared to the DOCA-salt rats (Fig. 3.18). 
There was no significant difference between control and DOCA+OX1RshRNA 
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groups at any point during the treatment (Fig. 3.18). At the end of the treatment, 
the final blood pressure measurements were as follows: control: 107.91±5.99 vs. 
DOCA-salt: 142.43±7.73 vs. DOCA+OX1RshRNA: 115.69±8.23 mmHg. Although 
there was a slight increase in DOCA-OX1RshRNA MAP, this was never a 
significant increase compared to control rats, but was significantly lower than the 
DOCA-salt group (P<0.01), indicating that OX1R knockdown within the PVN 
alleviates, at least in part, DOCA-salt induced hypertension, effectively reducing 
the normal MAP that is observed in DOCA-salt hypertension. 
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Figure 3.19: Heart rate recordings taken in the same rats that received BP 
measurements over the course of 18 days. The dotted line indicates beginning of 
DOCA-pellet and HS administration. There were no significant differences in heart 
rate between groups using a two-way ANOVA and Tukey post-hoc analysis. 
Despite the change in blood pressure between groups, there were no 
significant differences in heart rate (HR) between groups at any point during the 
treatment (Fig. 3.19). At the end of the 18-day measurements, measured heart 
rates were recorded as follows: controls (HR of 309.44±39.14 BPM), DOCA-salt 
(350.44±16.76 BPM), and DOCA-OX1RshRNA (324.82±34.59 BPM). 
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4 Discussion 
Approximately one-third of adults in the United States have hypertension, 
which puts them at a much higher risk for further cardiovascular events (Centers 
for Disease and Prevention 2011), effectively increasing the likelihood of 
premature death. Of that one-third of the population affected by hypertension, it is 
estimated that slightly more than half of those individuals also have salt sensitive 
hypertension (SSH) (Weinberger, Miller et al. 1986). However, despite 
advancements in hypertension research, the exact mechanism underlying its 
pathology has yet to be fully understood. Recently, the impact that central orexin 
function has on blood pressure regulation in various hypertensive rat models has 
been gaining attention (Schwimmer, Stauss et al. 2010, Lee, Dai et al. 2013, Li, 
Hindmarch et al. 2013, Lee, Tsai et al. 2015), with even more recent research 
observing the potential role of orexin signaling in SSH (Huber, Fan et al. 2017). 
However, the potential role of orexin in the DOCA-salt rat, a model for salt-
sensitive hypertension and hyperaldosteronism, has not yet been studied. To our 
knowledge, this is the first study conducted focused solely on the effect of orexin 
system function on the development and maintenance of hypertension in this 
model. Our study reports five major findings: I.) Expression of AVP and OX1R are 
increased in the PVN of DOCA-salt rats, and these increases are attenuated 
following prior PVN OX1R knockdown; II.) OXA expressing cells within the LH are 
increased in both DOCA-salt and DOCA-OX1RshRNA rats, and their axonal 
projections to the PVN are increased in the DOCA-OX1RshRNA rats; III.) Plasma 
AVP is increased following DOCA-salt treatment as well as OXA ICV, but is 
markedly decreased following PVN OX1R knockdown; IV.) Cardiac hypertrophy 
is present in DOCA-salt rats, and is at least partially attenuated following OX1R 
PVN knockdown; and lastly V.) The development of hypertension in DOCA-salt 
rats can be significantly attenuated following PVN OX1R knockdown. The 
combination of these results indicates a potential crucial role for central orexin 
system functioning in salt sensitive hypertension models. 
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 The PVN is a major area of cardiovascular integration, making it critical to 
proper blood pressure regulation (Pan 2004, Wei, Yu et al. 2009, Ribeiro, Panizza 
Hdo et al. 2015). One of the primary mechanisms underlying PVN regulation of 
blood pressure is the production and release of AVP from magnocellular neurons. 
Upon stimulation from peripheral osmolality and pressure changes, the CVOs, 
which lack a blood brain barrier, send afferent signals to the PVN, causing the 
production and subsequent release of AVP to the posterior pituitary, which 
releases it to peripheral circulation allowing it to cause both water reabsorption as 
well as vasoconstriction (Sunn, McKinley et al. 2003, Pan 2004, Kawano and 
Masuko 2010). Due to AVP’s established role in long term blood pressure 
regulation, as well as the presence of elevated AVP in many human hypertensive 
patients (Cowley, Cushman et al. 1981), RAAS activity, which can trigger AVP 
release, has become a major target for pharmaceutical intervention (Jarari, Rao 
et al. 2015). However, these pharmaceutical aids are not always effective, which 
can lead to the development of further complications such as resistant 
hypertension, making it important to find other forms of antihypertensive 
treatment. Previous work within our lab has found that PVN orexin functioning 
greatly influences both AVP release and subsequent sympathetic outflow in Dahl-
S rats, a genetic model of primary hypertension (Huber, Fan et al. 2017). Because 
AVP is essential to the development of DOCA-salt hypertension, we hypothesized 
that central orexin system functioning may play a role in DOCA hypertension. In 
agreement with numerous other studies (Grillo, Saravia et al. 1998, Pietranera, 
Saravia et al. 2004), we found that mRNA and protein expression of AVP are 
elevated within the brain of DOCA-salt rats, specifically in the PVN (Fig. 3.1 & 
3.2). We also observed an increase in plasma AVP (Fig. 3.5), similar to other 
studies (Saravia, Grillo et al. 1999). However, our study is novel in that it is the 
first to report elevated OX1R within the PVN (Fig. 3.3 & 3.4), as well as OXA in 
the LH (Fig. 3.9) following DOCA-salt treatment. This, combined with the 
implications of orexin function in blood pressure regulation led us to believe that 
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the over active orexin system in the DOCA model may contribute to the 
development of hypertension in this model.  
We then found that acute central administration of OXA resulted in a drastic 
increase in plasma AVP (Fig. 3.8), showing central OXA action elicits a substantial 
effect on AVP release from the neurohypophysis. We chose to determine the 
effects that chronic knockdown of PVN OX1R may have on the development of 
hypertension in SSH models, to discover the long-term impact orexin played on 
both central as well as peripheral AVP circulation. To do this, we used an adeno-
associated recombinant virus that specifically inhibits function of OX1R. Following 
previous models in which central knockdown of orexin receptor function resulted 
in attenuation of blood pressure increases (Shahid, Rahman et al. 2012, Lee, Dai 
et al. 2013), we performed bilateral microinjections of AAV2-OX1R-shRNA into 
the PVN of rats prior to DOCA pellet implantation. In agreement with our 
hypothesis, we found that OX1R PVN knockdown significantly reduced PVN 
OX1R and AVP mRNA (Fig. 3.10 & 3.12), as well as PVN OX1R and AVP protein 
expression (Fig. 3.11 & 3.13). In addition, chronic OX1R knockdown blocked the 
increase in plasma AVP induced by DOCA-salt treatment (Fig. 3.14B). 
Furthermore, significant decreases in blood pressure were observed in both the 
development and maintenance phases of DOCA-salt hypertension development 
(Fig. 3.18).  
Our results largely affirm our hypothesis that DOCA-pellet implantation 
causes increased orexin release from the LH which causes excitation of PVN 
magnocellular neurons through interaction with OX1R, which causes release of 
AVP into the peripheral circulation, resulting in vasoconstriction and increased 
blood volume, eventually leading to the development of hypertension. However, 
one discrepancy was that OXA axonal projections appeared to be more dense 
and over-active in the DOCA-OX1RshRNA rats, as opposed to the DOCA-salt 
rats, who did not appear to have much difference compared to the control. In 
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addition, although it was not significant, DOCA-salt rats also appeared to have a 
lower CSF OXA concentration (Fig. 3.14A), which we did not expect. However, 
this can be reasonably attributed to action of a feedback loop initiated through 
OX1R knockdown. The lack of OXA binding to OX1R in the PVN would be sensed 
and cause a greater input of axonal OXA to the PVN to try to elicit a response. 
Since the OX1R receptors were increased and abundant in the DOCA-salt rats, 
this same feedback loop may not have been initiated, although further studies 
must be conducted to adequately explain this discrepancy. Another possible 
explanation, more so for the decreased CSF OXA, is that the decrease of CSF 
OXA is indicative of a greater number of bound OXA molecules, meaning a 
greater increase of central orexin system function. Since the DOCA-
HS/OX1RshRNA rats had fewer active binding sites on OX1R, more OXA was left 
unbound, unable to elicit its actions through binding with its receptor. It is important 
to note that OXA immunoreactivity was however increased in both DOCA-salt as 
well as DOCA-OX1RshRNA rats within the LH, meaning that despite OX1R 
knockdown in the PVN, OXA production remained elevated due to the DOCA-salt 
treatment. This potentially strengthens the argument that OXA production is 
increased in SSH, and that the increase in PVN OXA axonal projections in the 
DOCA-OX1RshRNA rats compared to the DOCA-salt can be contributed to 
receptor availability. It also offers evidence that a potential method of hypertension 
treatment to be explored is through modulation of central orexin receptor activity, 
as opposed to the receptor ligands. 
There are a few reasons why we chose to use a DOCA model for salt-
sensitive hypertension. Approximately 10-30% of individuals are resistant to 
hypertensive drug treatment, such as ACE inhibitors and ANGII receptor 
blockade, and are diagnosed with resistant hypertension (Calhoun, Jones et al. 
2008, Lee, Dai et al. 2013, Sim, Bhandari et al. 2013). The DOCA model serves 
the dual purpose of allowing us to observe how orexin functions in another salt 
sensitive model, and more specifically allows us to accurately model 
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hyperaldosteronism, which is the primary cause of resistant hypertension 
(Mulatero, Rabbia et al. 2002, Eide, Torjesen et al. 2004, Viera and Neutze 2010). 
Our findings show that there is potential for orexin involvement in DOCA-salt 
hypertension development and maintenance due to increased presence and 
heightened functioning of the central orexin system, specifically through 
modulation of AVP production and release. We also chose to use a modified 
model of DOCA-salt rats to undertake this project. Namely, we omitted 
uninephrectomy from the protocol. We did this following a similar procedure that 
had been previously done (Kandlikar and Fink 2011). Excluding the 
uninephrectomy allows us to more accurately observe the direct effect that 
manipulations to orexin system function within the PVN has on hypertension 
development, without any adverse cardiovascular implications that kidney 
removal incurs (Kandlikar and Fink 2011). We believe that this model allows us to 
more closely mimic the development of human hypertension, which tends to occur 
more gradually, as opposed to the drastic, immediate spike that occurs in 
uninephrectomized rats. Lastly, since orexin function has been observed in 
primary hypertensive models such as the SHR and Dahl-S rat strains, and now 
has possible implications in the DOCA-salt model, this may point to an important 
underlying role for orexin in numerous different types of hypertension, making it 
more practical for human application. 
4.1 Implications 
Even with current hypertensive medications in use, the prevalence of 
hypertension and cardiovascular disease remains high. Research has been 
conducted that has evaluated the implications of orexin system function on blood 
pressure regulation, as well as SSH. The present research project offers the only 
look into the potential role for the orexin system in development and maintenance 
of DOCA-salt hypertension, primarily aldosteronism, the primary cause of 
resistant hypertension. This helps strengthen the notion that orexin is a major 
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regulator of cardiovascular function, and may help lead to future, more efficient 
pharmaceutical interventions targeting orexin function. 
4.2 Limitations 
A few limitations are present in this study. First, the use of tail-cuff 
plethysmography instead of blood pressure radio telemetry transducer 
implantation may have added more variability to the blood pressure recordings. 
Stress induced blood pressure changes may occur due to confinement in the 
plethysmography holder. However, careful consideration was taken when animals 
were introduced and acclimated to the procedure. This included a week of 
acclimation before even beginning the study, as well as daily acclimation to 
maintain proper comfort in the tubes. Furthermore, the efficacy of tail-cuff 
plethysmography has been adequately reviewed (Feng, Whitesall et al. 2008), 
and the blood pressure measured by tail cuff plethysmography has been shown 
to resemble that measured by the radio-telemetry transducer in undisturbed 
animals (Wilde, Aubdool et al. 2017). With all of this in mind, we do recognize the 
variability associated with tail-cuff plethysmography, but feel we have adequately 
reduced stress-induced blood pressure changes through our meticulous 
acclimation protocol.  
We further recognize that, during PVN mRNA testing, punching of the PVN 
is not exact. This means that some of the brain area surrounding the PVN area 
may be subjected to mRNA assessment as well, which may dilute our results. It 
is difficult to punch the PVN alone since it is such a small area, and for this reason, 
some variability in mRNA levels may be present. However, when paired with the 
use of protein immunostaining, the mRNA results become more reliable, since 
parallel increases in gene expression as well as the proteins they encode for are 
observed. 
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Lastly, our project only used male rats, without any female groups. It has 
been observed that testosterone plays a large role in the development of 
hypertension, and that males are more likely to have elevated blood pressure in 
both animals and humans alike. The findings of this research may not encompass 
the effects of DOCA-salt or PVN OX1R knockdown on females. Similar studies 
conducted using female rats will be the goal of future studies, as will the 
differences in orexin system function and subsequent hypertensive tendencies 
between male and female animals.  
Future directions to build from this study may include more chronic 
responses to OX1R knockdown in DOCA-salt rats, since most studies are only 
conducted over the course of three weeks using this model. Also, we would like 
to further study the peripheral effects of PVN OX1R knockdown in DOCA-salt rats, 
namely on kidney and heart function. Lastly, we would like to provide evidence of 
potential implications of orexin on adrenal gland dysfunction, which is essential to 
the pathogenesis of DOCA-salt development. 
4.3 Conclusion 
In conclusion, the present study has shown that there is potential of DOCA-
salt hypertension mediation through central orexin system functioning within the 
PVN. DOCA-salt treatment caused a significant increase in mRNA levels of AVP 
and OX1R within the PVN when compared to controls, and this increase was 
reduced following OX1R PVN knockdown. Protein expression of AVP and OX1R 
showed a similar pattern of increased expression in the PVN of DOCA-salt rats, 
and attenuation in DOCA-OX1RshRNA rat. Plasma AVP was also significantly 
increased following DOCA-salt treatment. In addition, central administration of 
OXA via ICV injection caused a notable increase in plasma AVP. Chronic OX1R 
PVN knockdown resulted in a large decrease in plasma AVP concentration 
compared to DOCA-salt treated rats. Furthermore, DOCA-salt as well as DOCA-
OX1RshRNA had increased OXA production in the LH. Also, DOCA-salt rats 
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showed increased cardiac hypertrophy, and this was partially attenuated by PVN 
OX1R knockdown. Lastly, chronic OX1R knockdown within the PVN significantly 
decreased the elevation in blood pressure that is commonly observed in DOCA-
salt hypertension. The results of this study show evidence of orexin system 
regulation of AVP production and release in the DOCA-rat model, and show that 
knockdown of OX1R function within the PVN significantly reduces hypertension in 
this rat model, offering a new potential mechanism underlying the development of 
salt-sensitive hypertension. 
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A Raw Data 
Table A.1: Raw data for 24-hr fecal output (g) following 3 weeks of treatment 
in each group. Bolded values utilized in control vs. DOCA-salt analysis. 
24-hr Fecal Output (grams)
Control DOCA-salt DOCA+OX1RshRNA 
1.34 2.9 3.64 
2.5 1.7 2.56 
0.95 4.69 2.3 
0.85 2.1 1.72 
- 6 2.84 
- - 3.47 
Table A.2: Raw data for 24-hr food intake (g) following 3 weeks of treatment 
in each group. Bolded values utilized in control vs. DOCA-salt analysis. 
24-hr Food Intake (grams)
Control DOCA-salt DOCA+OX1RshRNA 
22.7 25.3 25.5 
29.5 26.1 24.33 
27.67 19.77 25.9 
25.7 14.36 24.6 
- 22.59 21.06 
- - 24.54 
Table A.3: Raw data for 24-hr water intake (mL) following 3 weeks of 
treatment in each group. Bolded values utilized in control vs. DOCA-salt 
analysis. 
24-hr Water Intake (mL)
Control DOCA-salt DOCA+OX1RshRNA 
17.06 232.69 93.9 
29.4 163.31 177.1 
19.8 134.08 98.8 
77 
24.6 56 55.1 
- 120.54 94.58 
- - 213.15 
Table A.4: Raw data for 24-hr urine output (mL) following 3 weeks of treatment 
in each group. Bolded values utilized in control vs. DOCA-salt analysis. 
24-hr Urine Output (mL)
Control DOCA-salt DOCA+OX1RshRNA 
7.15 36.35 75.82 
7.85 90.45 91.65 
7.05 136.69 72.85 
5.15 121.77 32.25 
- 119.73 89.44 
- - 115.45 
Table A.5: Raw data for body weight increase (g) over the course of 3 weeks 
of treatment. Bolded values utilized in control vs. DOCA-salt analysis. 
3-Week Change in Weight (g)
Control DOCA-salt DOCA-OX1RshRNA 
116 59 57 
141 74 36.5 
148 74 27 
140 52 30 
111 98 35 
118 110 - 
62 105 - 
47 36 - 
50 27 - 
29 39 - 
- 58 - 
- 63 -
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- 22 - 
- 33 - 
- 24 - 
- 10 - 
- 18 - 
Table A.6: Raw data for mRNA levels of AVP and OX1R normalized to 
GAPDH expression in the PVN. 
PVN AVP mRNA/GAPDH 
Control DOCA-Salt DOCA-OX1RshRNA 
0.29861 4.075012 0.116243 
0.274243 1.604951 0.182224 
2.985346 3.499776 0.559579 
0.441796 4.777558 0.678754 
0.984581 0.469435 1.682963 
0.753647 0.392013 - 
0.735716 5.654253 - 
1.526056 6.808918 - 
- 0.999359 - 
PVN OX1R mRNA/GAPDH 
Control DOCA-Salt 
0.963092 1.318004 
0.939703 1.140277 
1.096772 1.407982 
- 1.056115 
79 
PVN OX1R mRNA/GAPDH 
Control DOCA-Salt DOCA-OX1RshRNA 
1.265941 1.927575 0.946485 
1.021909 1.18423 0.960295 
0.703364 1.087205 0.574349 
1.32161 1.474146 0.93185 
0.948758 1.04782 0.855416 
0.961832 1.088295 - 
0.776586 1.172714 - 
- 1.593106 - 
- 1.875779 - 
- 1.025059 - 
Table A.7: Raw Data for plasma AVP concentration (pg/ml) using ELISA. 
Plasma ELISA AVP Concentration (pg/ml) 
Control DOCA-salt 
14.74292 4.202917 
2.488958 7.873542 
8.144792 32.37125 
10.78833 30.225 
- 46.2918 
- 50.14979 
- 54.72375 
- 77.54875 
Table A.8: Raw Data for plasma AVP concentration (pg/ml) following OXA 
ICV using ELISA. 
Plasma ELISA AVP Concentration (pg/ml) 
80 
Saline (0.9%) ICV OXA (2nmol) ICV 
45.68792 106.2921 
62.52958 44.58083 
32.36083 97.18917 
Table A.9: Raw data for CSF OXA concentration (pg/ml) using ELISA. 
CSF ELISA OXA Concentration (pg/ml) 
Control DOCA-salt DOCA HS/ 
OX1RshRNA 
19.023 37.929 142.571 
111.537 71.762 154.929 
113.859 31.428 16.163 
86.943 - - 
136.727 - - 
Table A.10: Raw data for Plasma AVP concentration (pg/ml) using 
ELISA following chronic OX1R knockdown. 
Plasma ELISA AVP Concentration (pg/ml) 
Control DOCA-salt DOCA HS/ 
OX1RshRNA 
104.6883 254.7879 137.4867 
255.6463 253.6813 226.8013 
184.8092 193.9575 137.1929 
- 278.8671 - 
- 313.2242 - 
- 254.7879 -
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Table A.11: Raw data for heart weight to body weight ratio presented as 
a percentage of body weight following 3 weeks of treatment in each group. 
HW:BW (%) 
Control DOCA-salt DOCA-OX1RshRNA 
0.334 0.518 0.390331 
0.349 0.498 0.406241 
0.325 0.406 0.321127 
0.337 0.438 0.320442 
0.266055 0.394 0.321429 
0.317073 0.460252 - 
0.283333 0.402793 - 
0.272959 0.362155 - 
- 0.359694 - 
- 0.35533 - 
- 0.34359 - 
- 0.344262 - 
- 0.346405 - 
Table A.12: Raw data for MAP (mmHg) for 3 weeks of treatment in each group. 
MAP (mmHg) 
Week Measurement 
Point 
Control DOCA-salt DOCA-
OX1RshRNA 
Week 0 Baseline 120.5 111.1818 116.6 
105.4286 116.4545 101.7 
125.5 120.8571 117.8276 
112.8182 113.7778 111.8889 
125.3571 - - 
Week 1 T1 121.375 125.3636 112.6 
119.6154 132.875 105.6154 
82 
115.6667 127.3636 118 
119.375 126.625 113 
100.5333 - - 
T2 134.375 127.5 101.6667 
107.333 158.75 94.58824 
108.8571 138.111 117.25 
127.375 116.1 122.25 
106.9091 - - 
Week 2 T3 116.5556 136.1429 119.7778 
115.6111 129.5 112.75 
114.75 141.75 128.4286 
118.5 127.5 122.75 
118.9231 - - 
T4 107.875 127.2 114.125 
91.6 156.6154 120.1538 
127.75 153 138.1 
127.6364 134 112.3636 
115.1667 - - 
Week 3 T5 100.25 141.5 96.625 
90.14286 164.5 116.6154 
112.2308 133.625 136.6667 
125.6 130.0909 112.8889 
111.333 - - 
Table A.13: Raw data for HR (BPM) for three weeks during treatment in 
each group. 
Heart Rate (BPM) 
Week Measurement 
Point 
Control DOCA-salt DOCA-
OX1RshRNA 
83 
Week 0 Baseline 204 333 264 
327.5714 180.5455 346.5 
309.1875 418.5714 323.8966 
314.7273 431.8889 176.222 
372.6429 - - 
Week 1 T1 292.375 280.3636 221.5 
414.9231 379.375 329.5769 
193 399.4545 295.7143 
447.75 360.375 195.75 
418.6667 - - 
T2 313.75 484.5 231.25 
395.9524 402.625 290.7059 
475.4286 308.444 339.4167 
431.625 237.2 353.4167 
353 - - 
Week 2 T3 402 385.2857 325.5556 
370.5 355.0833 188.3333 
193 379.25 397.0714 
347.375 391.375 323 
333.3846 - - 
T4 248.875 378.1 352.125 
277.2 327.8462 255.8462 
352.58333 238.4 321.6 
400.1818 323.4615 318.5455 
121.8333 - - 
Week 3 T5 439.75 310.9286 227.75 
217.4286 347.5 323.3077 
279.6154 392.875 367.8889 
351.4 350.4545 380.3333 
259 - - 
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B Statistical Analysis 
Table B.1: Mean 24-hr fecal output in control and DOCA-salt groups. 
Fecal Output (g) 
Control DOCA-salt 
N 4 3 
Mean 1.41 4.263 
SD 0.7568 1.985 
SEM 0.3784 1.146 
Lower 95% CI 0.2058 -0.6669
Upper 95% CI 2.614 9.194 
Table B.2: Mean 24-hr fecal output in control, DOCA-salt, and 
DOCA-OX1RshRNA groups. 
Fecal Output (g) 
Control DOCA-salt OX1RshRNA 
N 4 5 6 
Mean 1.41 3.478 2.755 
SD 0.7568 1.818 0.7236 
SEM 0.3784 0.8131 0.2954 
Lower 95% CI 0.2058 1.22 1.996 
Upper 95% CI 2.614 5.736 3.514 
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Table B.3: Mean 24-hr urine output in control and DOCA-salt treatment groups. 
Urine Output (mL) 
Control DOCA-salt 
N 4 3 
Mean 6.8 126.1 
SD 1.156 9.259 
SEM 0.5781 5.346 
Lower 95% CI 4.96 103.1 
Upper 95% CI 8.64 149.1 
Table B.4: Mean 24-hr urine output in control, DOCA-salt, and 
DOCA-OX1RshRNA groups. 
Urine Output (mL) 
Control DOCA-salt OX1RshRNA 
N 4 5 6 
Mean 6.8 101 79.58 
SD 1.156 39.83 27.67 
SEM 0.5781 17.81 11.3 
Lower 95% CI 4.96 51.54 50.54 
Upper 95% CI 8.64 150.5 108.6 
Table B.5: Mean 24-hr water intake in control and DOCA-salt treatment groups 
Water Intake (mL) 
86 
Control DOCA-salt 
N 4 3 
Mean 22.72 176.7 
SD 5.438 50.65 
SEM 2.719 29.24 
Lower 95% CI 14.06 50.87 
Upper 95% CI 31.37 302.5 
Table B.6: Mean 24-hr water intake in control, DOCA-salt, and 
DOCA-OX1RshRNA groups. 
Water Intake (mL) 
Control DOCA-salt OX1RshRNA 
N 4 5 6 
Mean 22.72 141.3 122.1 
SD 5.438 64.41 59.83 
SEM 2.719 28.81 24.43 
Lower 95% CI 14.06 61.35 59.31 
Upper 95% CI 31.37 221.3 184.9 
Table B.7: Mean 24-hr food intake in control and DOCA-salt treatment groups. 
Food Intake (g) 
Control DOCA-salt 
N 4 3 
87 
Mean 26.39 18.91 
SD 2.91 4.182 
SEM 1.455 2.415 
Lower 95% CI 21.76 8.517 
Upper 95% CI 31.02 29.3 
Table B.8: Mean 24-hr food intake in control, DOCA-salt, and 
DOCA-OX1RshRNA groups. 
Food Intake (g) 
Control DOCA-salt OX1RshRNA 
N 4 5 6 
Mean 26.39 21.62 24.32 
SD 2.91 4.761 1.711 
SEM 1.455 2.129 0.6986 
Lower 95% CI 21.76 15.71 22.53 
Upper 95% CI 31.02 27.54 26.12 
Table B.9: Mean 3-week body weight increases in control and DOCA-
salt treatment groups. 
Body Weight Change (g) 
Control DOCA-salt 
N 6 7 
Mean 129 81.71 
SD 15.75 22.82 
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SEM 6.429 8.626 
Lower 95% CI 112.5 60.61 
Upper 95% CI 145.5 102.8 
Table B.10: Mean 3-week body weight increases in control, DOCA-salt, 
and DOCA-OX1RshRNA groups. 
Body Weight Change (g) 
Control DOCA-salt OX1RshRNA 
N 10 17 5 
Mean 86 53.06 37.1 
SD 54.2 31.08 11.76 
SEM 16.34 7.539 5.259 
Lower 95% CI 49.59 37.08 22.5 
Upper 95% CI 122.4 69.04 51.7 
Table B.11: Mean PVN AVP and OX1R mRNA expression normalized to 
GAPDH. 
PVN AVP mRNA/GAPDH 
Control DOCA-salt OX1RshRNA 
N 8 9 5 
Mean 1 3.142 0.644 
SD 0.9007 2.374 0.6284 
SEM 0.3185 0.7914 0.281 
Lower 95% CI 0.247 1.317 -0.1363
Upper 95% CI 1.753 4.967 1.424 
PVN OX1R mRNA/GAPDH 
Control DOCA-salt 
N 3 4 
Mean 0.9999 1.231 
SD 0.08474 0.1609 
SEM 0.04893 0.08047 
Lower 95% CI 0.7893 0.9745 
Upper 95% CI 1.21 1.487 
PVN OX1R mRNA/GAPDH 
Control DOCA-salt OX1RshRNA 
N 7 10 5 
Mean 1 1.348 0.8537 
SD 0.2297 0.3461 0.1613 
SEM 0.08683 0.1094 0.07215 
Lower 95% CI 0.7875 1.1 0.6534 
Upper 95% CI 1.212 1.595 1.054 
Table B.12: Mean plasma AVP Concentration (pg/ml) in control and DOCA-
salt groups. 
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Plasma ELISA AVP Concentration (pg/ml) 
Control DOCA-salt 
N 4 8 
Mean 9.041 37.94 
SD 5.141 24.5 
SEM 2.571 8.661 
Lower 95% CI 0.8603 17.46 
Upper 95% CI 17.22 58.42 
Table B.13: Mean plasma AVP Concentration (pg/ml) following saline or 
OXA ICV. 
Plasma ELISA AVP Concentration (pg/ml) 
Saline (0.9%) ICV OXA (2nmol) ICV 
N 3 3 
Mean 46.86 82.69 
SD 15.12 33.31 
SEM 8.729 19.23 
Lower 95% CI 9.303 -0.0679
Upper 95% CI 84.42 165.4 
Table B.14: Mean CSF OXA concentration (pg/ml) in all groups. 
CSF OXA Concentration (pg/ml) 
Control DOCA-salt OX1RshRNA 
N 5 3 3 
Mean 93.62 47.04 104.6 
SD 45.27 21.66 76.8 
91 
SEM 20.25 12.5 44.34 
Lower 95% CI 37.41 -6.755 -86.22
Upper 95% CI 149.8 100.8 295.3 
Table B.15: Mean Plasma AVP concentration (pg/ml) in all treatment groups. 
Plasma AVP Concentration (pg/ml) 
Control DOCA-salt OX1RshRNA 
N 3 5 3 
Mean 181.7 258.9 167.2 
SD 75.53 43.62 51.65 
SEM 43.61 19.51 29.82 
Lower 95% CI -5.903 204.7 38.85 
Upper 95% CI 369.3 313.1 295.5 
Table B.16: Mean heart weight to body weight ratio presented as percent 
body weight in control, DOCA-salt, and DOCA-OX1RshRNA groups. 
HW:BW (%) 
Control DOCA-salt OX1RshRNA 
N 4 5 6 
Mean 0.3106 0.4022 0.3519 
SD 0.03188 0.05974 0.04271 
SEM 0.01127 0.01657 0.0191 
Lower 95% CI 0.2839 0.3661 0.2989 
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Upper 95% CI 0.3372 0.4383 0.4049 
Table B.17: Mean MAP over the course of 3 weeks in control, DOCA-salt, 
and OX1RshRNA rats. 
MAP (mmHg) 
Base T1 T2 T3 T4 T5 
C
on
tr
ol
 
N 5 5 5 5 5 5 
Mean 117.92
1 
115.31
3 
116.97 116.868 114.006 107.911 
SD 8.682 8.519 12.953 1.806 15.130 13.395 
SEM 3.883 3.810 5.793 0.808 6.766 5.990 
D
O
C
A
-s
al
t 
N 4 4 4 4 4 4 
Mean 115.56
7 
128.05
7 
135.115 133.723 142.704 142.429 
SD 4.131 3.317 18.140 6.503 14.326 15.468 
SEM 2.066 1.658 9.070 3.251 7.163 7.734 
D
O
C
A
-O
X1
R
sh
R
N
A
 N 4 4 4 4 4 4 
Mean 112.00
4 
112.30
4 
108.939 120.927 121.186 115.699 
SD 7.331 5.091 12.975 6.526 11.759 16.454 
SEM 3.665 2.545 6.488 3.263 5.880 8.227 
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Table B.18: Mean heart rate over the course of 3 weeks in control, DOCA-
salt, DOCA-OX1RshRNA rat groups. 
HR (BPM) 
Base T1 T2 T3 T4 T5 
C
on
tr
ol
 
N 5 5 5 5 5 5 
Mean 305.626 353.34
3 
393.951 329.252 280.135 309.439 
SD 62.041 107.70
2 
63.583 80.473 106.894 87.523 
SEM 27.745 48.166 28.435 35.989 47.804 39.141 
D
O
C
A
-s
al
t 
N 4 4 4 4 4 4 
Mean 341.001 354.89
2 
358.192 377.749 316.952 350.440 
SD 115.597 52.185 108.077 15.900 57.938 33.519 
SEM 57.798 26.092 54.039 7.950 28.969 16.759 
D
O
C
A
-O
X1
R
sh
R
N
A
 N 4 4 4 4 4 4 
Mean 277.655 260.63
5 
303.697 308.490 312.029 324.820 
SD 76.055 62.517 55.273 87.151 40.407 69.189 
SEM 38.027 31.259 27.636 43.576 20.204 34.594 
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Table B.19: Unpaired two-tail t-test analysis of 24-hr fecal output between 
control and DOCA-salt treatment groups. 
Unpaired Two-Tail T-test – Fecal Output 
P value 0.043 
P value summary * 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=2.697 df=5 
Table B.20: One-way ANOVA analysis of 24-hr fecal output between all 
treatment groups. 
Fecal Output 
ANOVA Summary 
F 3.295 
P-value 0.0724 
R-square 0.3545 
ANOVA Table SS DF MS 
Treatment 
(Between 
Columns) 
9.642 2 4.821 
Residual (Within 
Columns) 
17.56 12 1.463 
95 
Total 27.2 14 
Table B.21: Unpaired two-tail analysis of 24-hr food intake between control 
and DOCA-salt treatment groups. 
Unpaired Two-Tail T-test – Food Intake 
P value 0.0371 
P value summary * 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=2.820 df=5 
Table B.22: One-way ANOVA analysis of 24-hr food intake between all groups. 
Food Intake 
ANOVA Summary 
F 2.374 
P-value 0.1353 
R-square 0.2835 
ANOVA Table SS DF MS 
Treatment 
(Between 
Columns) 
51.73 2 25.87 
96 
Residual (Within 
Columns) 
130.7 12 10.89 
Total 182.5 14 
Table B.23: Unpaired two-tailed t-test analysis of 24-hr water intake 
between control and DOCA 
Unpaired Two-Tail T-test – Water Intake 
P value 0.0015 
P value summary ** 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=6.240 df=5 
Table B.24: One-way ANOVA analysis of 24-hr water intake between groups, 
as well as Tukey post-hoc analysis 
Water Intake 
ANOVA Summary 
F 6.124 
P-value 0.0147 
R-square 0.5051 
ANOVA Table SS DF MS 
97 
Treatment 
(Between 
Columns) 
35302 2 17651 
Residual (Within 
Columns) 
34584 12 2882 
Total 69886 14 
Tukey Mean Diff. 95% CI Significant? Summary 
Control vs. 
DOCA-salt 
-118.6 -214.7 to -
22.53
Yes * 
Control vs. 
OX1RshRNA 
-99.39 -191.8 to -
6.940
Yes * 
DOCA-salt vs. 
OX1RshRNA 
19.22 -67.51 to
105.9
No ns 
Table B.25: Unpaired two-tail t-test analysis of 24-hr urine output between 
control and DOCA-salt groups. 
Unpaired Two-Tail T-test – Urine Output 
P value < 0.0001 
P value summary **** 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
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t, df t=26.36 df=5 
Table B.26: One-way ANOVA analysis of 24-hr urine output between groups, 
as well as Tukey post-hoc analysis. 
Urine Output 
ANOVA Summary 
F 12.51 
P-value 0.0012 
R-square 0.6758 
ANOVA Table SS DF MS 
Treatment 
(Between 
Columns) 
21223 2 10612 
Residual (Within 
Columns) 
10180 12 848.3 
Total 31403 14 
Tukey Mean Diff. 95% CI Significant? Summary 
Control vs. 
DOCA-salt 
-94.2 -146.3 to -
42.07
Yes ** 
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Control vs. 
OX1RshRNA 
-72.78 -122.9 to -
22.62
Yes ** 
DOCA-salt vs. 
OX1RshRNA 
21.42 -25.63 to
68.47
No ns 
Table B.27: Unpaired two-tail t-test analysis of 3-week weight gain 
between control and DOCA-salt groups. 
Unpaired Two-Tail T-test – Change in Body Weight 
P value 0.0013 
P value summary ** 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=4.266 df=11 
Table B.28: One-way ANOVA analysis of 3-week weight gain as well as 
HW:BW between groups, as well as Tukey post-hoc analysis. 
Weight Gain 
ANOVA Summary 
F 6.843 
P-value 0.0037 
R-square 0.3206 
ANOVA Table SS DF MS 
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Treatment 
(Between 
Columns) 
16021 2 8011 
Residual (Within 
Columns) 
33948 29 1171 
Total 49969 31 
Tukey Mean Diff. 95% CI Significant? Summary 
Control vs. 
DOCA-salt 
43.14 9.467 to 
76.82 
Yes ** 
Control vs. 
OX1RshRNA 
59.1 12.82 to 
105.4 
Yes * 
DOCA-salt vs. 
OX1RshRNA 
15.96 -27.03 to
58.95
No ns 
HW:BW 
ANOVA Summary 
F 8.547 
P-value 0.0017 
R-square 0.4263 
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ANOVA Table SS DF MS 
Treatment 
(Between 
Columns) 
0.04254 2 0.02127 
Residual (Within 
Columns) 
0.05724 23 0.002489 
Total 0.09978 25 
Tukey Mean Diff. 95% CI Significant? Summary 
Control vs. 
DOCA-salt 
-0.09164 -0.1478 to -
0.03550
Yes ** 
Control vs. 
OX1RshRNA 
-0.04136 -0.1126 to
0.02986
No ns 
DOCA-salt 
vs. 
OX1RshRNA 
0.05028 -0.01547 to
0.1160
No ns 
Table B.29: Unpaired two-tail, and one-tail t-test analysis of PVN AVP and 
OX1R mRNA/GAPDG between groups. 
Unpaired Two-Tail T-test – PVN AVP mRNA/GAPDH 
P value 0.03 
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P value summary * 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=2.397 df=15 
Unpaired One-Tail T-test – PVN OX1R mRNA/GAPDH 
P value 0.0383 
P value summary * 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? One-tailed 
t, df t=2.226 df=5 
Table B.30: One-way ANOVA analysis of PVN AVP mRNA/GAPDG 
between groups, as well as Tukey post-hoc analysis. 
PVN AVP mRNA/GAPDH 
ANOVA Summary 
F 5.085 
P value 0.017 
R-square 0.3486 
ANOVA Table SS DF MS 
Treatment 
(Between 
Columns) 
28.02 2 14.01 
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Residual (Within 
Columns) 
52.35 19 2.755 
Total 80.37 21 
Tukey Mean Diff. 95% CI Significant? Summary 
Control vs. 
DOCA-salt 
-2.142 -4.191 to -
0.09335
Yes * 
Control vs. 
OX1RshRNA 
0.356 -2.048 to 2.760 No ns 
DOCA-salt 
vs. 
OX1RshRNA 
2.498 0.1464 to 4.850 Yes * 
Table B.31: One-way ANOVA analysis of PVN OX1R mRNA/GAPDH 
between groups, as well as Tukey post-hoc analysis. 
PVN OX1R mRNA/GAPDH 
ANOVA Summary 
F 6.168 
P value 0.0086 
R-square 0.3937 
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ANOVA Table SS DF MS 
Treatment 
(Between 
Columns) 
0.9729 2 0.4865 
Residual (Within 
Columns) 
1.499 19 0.07887 
Total 2.472 21 
Tukey Mean Diff. 95% CI Significant? Summary 
Control vs. 
DOCA-salt 
-0.3476 -0.6992 to
0.004009
No ns 
Control vs. 
OX1RshRNA 
0.1463 -0.2714 to
0.5641
No ns 
DOCA-salt 
vs. 
OX1RshRNA 
0.4939 0.1031 to 
0.8847 
Yes * 
Table B.32: Unpaired T-test of plasma AVP concentration between saline 
and OXA ICV rats. 
Unpaired One-Tail T-test – Saline ICV vs. OXA ICV Plasma AVP 
P value 0.0825 
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P value summary ns 
Significantly different? (P < 0.05) No 
One- or two-tailed P value? One-tailed 
t, df t=1.696 df=4 
P value 0.0825 
Table B.33: Unpaired T-test of plasma AVP concentration between control 
and DOCA-salt rats. 
Unpaired Two-Tailed T-test – Control vs. DOCA-salt Plasma AVP 
P value 0.0457 
P value summary * 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=2.281 df=10 
P value 0.0457 
Table B.34: One-way ANOVA analysis of CSF OXA concentration (pg/ml). 
CSF OXA Concentration 
ANOVA Summary 
F 1.114 
P-value 0.3744 
R-square 0.2178 
ANOVA Table SS DF MS 
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Treatment 
(Between 
Columns) 
5828 2 2914 
Residual (Within 
Columns) 
20932 8 2616 
Total 26760 10 
Table B.35: One-way ANOVA analysis of plasma AVP concentration (pg/
ml) following chronic OX1R knockdown 
Plasma AVP Concentration (pg/ml) 
ANOVA Summary 
F 3.248 
P-value 0.0928 
R-square 0.4481 
ANOVA Table SS DF MS 
Treatment 
(Between 
Columns) 
19776 2 9888 
Residual (Within 
Columns) 
24356 8 3044 
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Total 44131 10 
Table B.36: Unpaired two-tail t-test of plasma AVP concentration between 
DOCA-salt and DOCA-HS/OX1RshRNA rats. 
Unpaired Two-Tailed T-test – DOCA-salt vs. DOCA-HS/OX1RshRNA 
Plasma AVP 
P value 0.0354 
P value summary * 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=2.704 df=6 
P value 0.0354 
Table B.37: Two-way ANOVA analysis of 3 week MAP between groups, as 
well as Tukey post-hoc analysis. 
MAP 
ANOVA 
Summary 
%Total 
Variation 
P Value P Value 
Summary 
Significant? 
Interaction 12.98 0.1111 ns No 
Row Factor 5.927 0.1977 ns No 
Column Factor 34.25 < 0.0001 **** Yes 
ANOVA Table SS DF MS P value 
Interaction 2089 10 208.9 P = 0.1111 
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Row Factor 953.9 5 190.8 P = 0.1977 
Column Factor 5512 2 2756 P < 0.0001 
Residual 7540 60 125.7 
Total 16094.9 77 
MAP 
Time 
Point 
Tukey Mean 
Diff 
95% CI Significant? Summary 
Base Control vs. DOCA-
HS 
2.353 -15.72 to
20.42
No ns 
Control vs. 
DOCA+OX1RshRNA 
5.917 -12.16 to
23.99
No ns 
DOCA-HS vs. 
DOCA+OX1RshRNA 
3.564 -15.49 to
22.61
No ns 
T1 Control vs. DOCA-
HS 
-12.74 -30.82 to
5.328
No ns 
Control vs. 
DOCA+OX1RshRNA 
3.009 -15.06 to
21.08
No ns 
109 
DOCA-HS vs. 
DOCA+OX1RshRNA 
15.75 -3.297 to
34.80
No ns 
T2 Control vs. DOCA-
HS 
-18.15 -36.22 to
-0.07364
Yes * 
Control vs. 
DOCA+OX1RshRNA 
8.031 -10.04 to
26.10
No ns 
DOCA-HS vs. 
DOCA+OX1RshRNA 
26.18 7.127 to 
45.23 
Yes ** 
T3 Control vs. DOCA-
HS 
-16.86 -34.93 to
1.217
No ns 
Control vs. 
DOCA+OX1RshRNA 
-4.059 -22.13 to
14.01
No ns 
DOCA-HS vs. 
DOCA+OX1RshRNA 
12.8 -6.253 to
31.85
No ns 
T4 Control vs. DOCA-
HS 
-28.7 -46.77 to
-10.63
Yes *** 
Control vs. 
DOCA+OX1RshRNA 
-7.18 -25.25 to
10.89
No ns 
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DOCA-HS vs. 
DOCA+OX1RshRNA 
21.52 2.469 to 
40.57 
Yes * 
T5 Control vs. DOCA-
HS 
-34.52 -52.59 to
-16.45
Yes **** 
Control vs. 
DOCA+OX1RshRNA 
-7.788 -25.86 to
10.28
No ns 
DOCA-HS vs. 
DOCA+OX1RshRNA 
26.73 7.681 to 
45.78 
Yes ** 
Table B.38: Two-way ANOVA analysis of 3-week HR between groups. 
Heart Rate 
ANOVA 
Summary 
%Total 
Variation 
P Value P Value 
Summary 
Significant? 
Interaction 7.599 0.8304 ns No 
Row Factor 4.839 0.605 ns No 
Column Factor 7.824 0.0603 ns No 
ANOVA Table SS DF MS P value 
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Interaction 34118 10 3412 P = 0.8304 
Row Factor 21726 5 4345 P = 0.6050 
Column Factor 35129 2 17565 P = 0.0603 
Residual 358005 60 5967 
Total 448978 77 
